

# The Design and Use of Animal Models for Translational Research in Bone Tissue Engineering and Regenerative Medicine

George F. Muschler, M.D.,<sup>1</sup> Vivek P. Raut, M.S.,<sup>1</sup> Thomas E. Patterson, Ph.D.,<sup>1</sup>  
Joseph C. Wenke, Ph.D.,<sup>2</sup> and Jeffrey O. Hollinger, D.D.S., Ph.D.<sup>3</sup>

This review provides an overview of animal models for the evaluation, comparison, and systematic optimization of tissue engineering and regenerative medicine strategies related to bone tissue. This review includes an overview of major factors that influence the rational design and selection of an animal model. A comparison is provided of the 10 mammalian species that are most commonly used in bone research, and existing guidelines and standards are discussed. This review also identifies gaps in the availability of animal models: (1) the need for assessment of the predictive value of preclinical models for relative clinical efficacy, (2) the need for models that more effectively mimic the wound healing environment and mass transport conditions in the most challenging clinical settings (e.g., bone repair involving large bone and soft tissue defects and sites of prior surgery), and (3) the need for models that allow more effective measurement and detection of cell trafficking events and ultimate cell fate during the processes of bone modeling, remodeling, and regeneration. The ongoing need for both continued innovation and refinement in animal model systems, and the need and value of more effective standardization are reinforced.

## Introduction

**T**HIS REVIEW IS WRITTEN with several goals: (1) To provide a rational paradigm of generalizable principles that will guide investigators in the choice of optimal model systems and in the design of new model systems. (2) To provide an overview of the current animal models that are available for exploring and advancing therapeutic options for bone repair and regeneration. (3) To define some of the current deficiencies in the current models or their use, and to articulate some opportunities for further development. In doing so, the authors hope to contribute to the ongoing professional and cultural dialog regarding the use of animal models, and to accelerate the rate of innovation and effective development of new and more effective clinical therapies and patient care.

Tissue engineering and regenerative medicine related to bone include a broad range of settings and approaches that seek to repair, augment, replace, or regenerate bone tissue.<sup>1,2</sup> Formation of new tissue by bone-forming cells (osteogenic cells) is a central feature of each of these goals, and can broadly be placed into four major strategic categories of cell therapy: (1) “targeting” local stem cells and progenitors at a local site (e.g., scaffolds, bioactive factors, and biophysical methods), (2) “transplantation” of stem cells or progenitors

(harvest from one site and transplantation to a new site, with or without processing to increase concentration or prevalence in a local site), (3) “homing” of stem cells and/or progenitors into a wound site from regional tissues or systemic circulations (e.g., using native bioactive factors or selective targeting using selective binding or magnetic fields), and (4) “modification” of stem cells or progenitors (e.g., *in vitro* expansion or adaptation with or without transient or durable genetic modification that alters or enhances performances.<sup>1</sup> Experiments designed to assess questions and optimize conditions related to the clinical translation of each of these strategies require means of systematic control and modification of key variables associated with the implementation of these strategies. A single ideal model is not currently available in which bone tissue regeneration can or should be assessed. However, the most effective model systems for bone regeneration research and development should meet several essential criteria. (1) They should provide an environment that matches, to the greatest extent possible, the clinical and biological environment and material formulation in which the methods under assessment will be used. (2) They should provide objective and quantifiable parameters (metrics) to assess the success (quantity and quality) and functional performance of the regenerated bone tissue. (3) They should detect and

<sup>1</sup>Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.

<sup>2</sup>United States Army Institute of Surgical Research, Fort Sam Houston, Texas.

<sup>3</sup>Department of Biomedical Engineering and Biological Sciences, Carnegie Mellon University, Pittsburgh, Pennsylvania.

Report Documentation Page				Form Approved OMB No. 0704-0188	
Public reporting burden for the collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to a penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.					
1. REPORT DATE <b>01 FEB 2010</b>		2. REPORT TYPE <b>N/A</b>		3. DATES COVERED <b>-</b>	
4. TITLE AND SUBTITLE <b>The design and use of animal models for translational research in bone tissue engineering and regenerative medicine</b>				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) <b>Muschler G. F., Raut V. P., Patterson T. E., Wenke J. C., Hollinger J. O.,</b>				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) <b>United States Army Institute of Surgical Research, JBSA Fort Sam Houston, TX</b>				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION/AVAILABILITY STATEMENT <b>Approved for public release, distribution unlimited</b>					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT					
15. SUBJECT TERMS					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT <b>UU</b>	18. NUMBER OF PAGES <b>27</b>	19a. NAME OF RESPONSIBLE PERSON
a REPORT <b>unclassified</b>	b ABSTRACT <b>unclassified</b>	c THIS PAGE <b>unclassified</b>			

predict clinically relevant differences in biological performance between methods (i.e., the relative rate and frequency of success).

### Bone as a Composite Tissue—Implications in Defining Metrics for Assessment


Rational approaches for animal models to assess bone regeneration demand an understanding of the nature of bone as a complex and highly organized dynamic and heterogeneous connective tissue that provides biological function in many domains: mechanical load bearing and force transmission, immunologic function (leukogenesis and lymphogenesis), mass transport (erythropoiesis), coagulation (thrombogenesis), energy storage (fat deposition), and calcium homeostasis (Fig. 1).

The defining feature of bone is an extracellular collagen based matrix (osteoid) that is mineralized with a unique carbonated hydroxyapatite. This mineralized bone matrix provides the unique biomechanical properties of elastic resistance to deformation in compression and bending that allows bone to transmit the mechanical forces enabling mobility, mastication, and respiration, and to shield critical organs from trauma (e.g., the eyes and brain). As a result, almost all studies of bone tissue engineering utilize an assessment of volume, distribution, and density of mineralized matrix as a primary outcome measure (e.g., radiographs, computed tomography, or X-ray absorptiometry). MicroCT imaging in particular has revolutionized the utility of many *in vivo* models. MicroCT may provide quantitative information regarding three-dimensional pattern and distribution of mineralization at the macromolecular level of bone structure, enabling assessment of trabecular number, thickness, connectivity, and mineral density, which are correlated strongly with mechanical properties and the status of modeling and remodeling within a region.

However, bone is more than just a mineralized tissue. Assessments of other parameters are necessary to provide a full quantitative description of the quality of bone. Mineralized bone matrix, despite its unique features and elegance, represents only a fraction of the overall volume of skeletal tissues. In normal cancellous trabecular bone, mineralized bone matrix generally represents less than 25% of the total tissue volume. The majority of the volume of bone tissue consists of a highly variable mixture of fat, fibrous tissue, and hematopoietic tissues that contain an equally variable, but generally rich plexus of arteries, veins, and venous sinusoids.

Histological assessment is generally the key secondary metric of outcome. Histology is necessary to characterize the pattern and distribution of cellularity in the mineralized bone tissue compartment and/or the kinetics of bone formation and mineralization (osteocytes, osteoblasts, lining cells, and osteoclasts). Histology is also necessary to characterize the nature of tissue within the nonmineralized intertrabecular regions of bone with respect to hematopoietic cells, fat, fibrous tissue, vascularity, and the status of any local inflammatory response or residual implant materials. Immunohistochemistry and *in situ* hybridization can further refine characterization of cell phenotypes based on local matrix, cell surface markers, intracellular markers, and gene expression.

Chemical characterization of the composition of both organic matrix (collagen and noncollagenous proteins) and/or



**FIG. 1.** Histological cross section of bone stained with toluidine blue. Various types of cells present in the bone niche are marked. These include osteoblasts (O), hematopoietic cells (H), vascular lining cells (V), lining cells (L), and fat (F). The mineralized bone appears as a solid dark area. Unmineralized osteoid appears as a pale blue area under osteoblasts. Color images available online at [www.liebertonline.com/ten](http://www.liebertonline.com/ten).

mineral is sometimes needed to distinguish bone matrix and true biological mineralization (carbonated microcrystalline hydroxyapatite) from scar or regions of precipitation of amorphous calcium phosphate salts. However, although important as biological parameters, in the absence of known or suspected genetic, hormonal, or nutritional abnormalities, or biochemical defects, chemical and mineral analyses of new bone tissue are not generally key metrics.

Mechanical performance is, in many settings, the ultimate test of the success of bone tissue engineering. Although the volume, distribution, and density of mineralized bone matrix may be a strong predictor of the mechanical properties of new bone tissue, this correlation is not perfect, particularly in the setting of ongoing remodeling in or around an implant. As a result, mechanical testing, at a whole bone or local bone level, remains a highly relevant parameter to assess the outcome of new bone tissue (i.e., modulus, strength, ductility, and fatigue resistance). Mechanical integration of new bone tissue with adjacent bone and soft tissues or with durable implant materials (e.g., endoprosthetics) is also highly relevant to many clinical applications. Functional bone provides broad surfaces and focal points of attachment for specialized tendons, ligaments, muscle cartilage, teeth, and nails (i.e., claws or hoofs). Similarly, the capacity of a tissue-engineered construct to develop appropriate nonintegrated surfaces can be equally important in some clinical situations (e.g., gliding surfaces for specialized tendons or bursa, and surfaces that support membrane tissues lining the skull, spinal canal [dura], and chest cavity [pleura]).

The recent evolution of stem cell and progenitor cell biology has also highlighted the fact that bone and bone marrow also serve as a niche and reservoir for a heterogeneous population of stem cells and progenitors capable of contrib-

uting to the formation of all of the above tissues (not only for bone, fat, vascular cells, and hematopoietic cells, but also for cells capable of generating other tissues, such as liver and nerve).<sup>2-7</sup> The capacity of regenerated bone to become repopulated with an appropriate population of stem cells and progenitors has not yet become a clinically relevant metric of outcome, but may be exploited more in the future. Repopulation with stem and progenitor cells may be a predictive factor of the long-term performance and remodeling potential of the new tissue. This may be particularly important to long-term clinical success in settings of regional stem cell and progenitor cell deficiency, such as radiation injury, large segmental defects, or congenital pseudoarthrosis.

### ***In Vivo* and *In Vitro* Animal Models for Bone Repair**

The discipline of engineering translates fundamental knowledge in physics, chemistry, and biology into materials, devices, systems, and strategies to achieve practical benefits. Engineered solutions, almost by definition, include the systematic assessment and attempt to optimize each variable that may contribute to success or failure. Tissue engineering and its clinical outlet in regenerative medicine apply this conceptual framework to advance the repair, replacement, or regeneration of organs and tissues.<sup>1,3,8,9</sup> As a discipline that is fundamentally grounded in living systems, the design and development of quantitative and reproducible model systems for *in vitro* or *in vivo* study is essential to the rational development of tissue engineering. The tool sets available in existing *in vitro* and *in vivo* models are, as they always have been, incomplete. There will always be a need to design and develop new animal models to address new questions or to better resolve old questions in a more rigorous and standardized fashion.

*In vitro* assays using cell culture preparations have found increasing use in the discovery of fundamental biological mechanisms (e.g., transcription, translation, signaling events and processes, and cell cycle regulation), characterization of the effects of materials on isolated cell function, and for screening large numbers of compounds for biological activity, toxicity, or immunogenicity.<sup>10,11</sup> Bioreactor systems have begun to expand the application of these systems of discovery to include three-dimensional constructs and some multicellular composites.<sup>12</sup> However, *in vitro* systems are inevitably limited in their capacity to recreate the complex *in vivo* environment, and are ultimately incapable of predicting *in vivo* or clinical performance in many settings, particularly in settings of tissue engineering and regeneration. Moreover, new and promising therapies such as systemic doses of parathyroid hormone cannot be evaluated in *in vitro* models.

*In vivo* models (i.e., animal models) are required when *in vitro* systems cannot provide a reproducible approximation of the real-life *in vivo* or clinical setting. Some obvious and common examples include the kinetics of delivery and distribution of drugs or bioactive factors; the biocompatibility and degradation properties of implant materials<sup>13</sup>; the effect of intervention on the local secretion or release of cytokines and the flux and stability of *in vivo* cytokine gradients (which define the heterogeneous and locally varying chemical environment of wounds); the patterns and distribution of gradients associated with the mass transport of oxygen and other nutrients<sup>1</sup>; the survival of cells and tissue after trans-

plantation; regional distribution cellular kinetics (proliferation, migration, differentiation, matrix synthesis, apoptosis, and necrosis) through tissue compartments<sup>3</sup>; migration of cells through vascular systems (both immune/inflammatory response and stem cell or progenitor cell homing)<sup>14</sup>; the multicellular processes associated with budding angiogenesis and revascularization to reestablish the flow of blood in a tissue; and the heterogeneous environment of mechanical stimuli associated with muscle contraction and mechanical deformation through extrinsic forces or intrinsic movement (e.g., flexion and extension of a limb or spine) and vascular pulsation.<sup>15</sup> Although selected aspects of these processes can be studied *in vitro*, none of these environments or processes can be created reliably *in vitro* outside of very narrow and uniform conditions. Moreover, *in vivo*, all of these systems vary simultaneously across time and space, which cannot be reduced or isolated during embryonic development and morphogenesis, during disease initiation and progression, during a response to injury or therapeutic intervention, or during aging.

### **Domains of Use for Animal Models**

Animal models play a critical role in many domains of study in medicine and biology. These can generally be categorized in three domains: (1) fundamental discovery, (2) feasibility and bioactivity testing, and (3) clinical modeling and efficacy prediction.

Questions related to fundamental discovery involve discovery and characterization of biological mechanisms, addressing the questions framed in the context of, "How do things work?" and "What is the origin and mechanism of morphogenesis or disease?" These questions are inevitably addressed in highly defined animal models (both genetically and immunologically) that provide a high level of reproducibility. Fundamental discovery research demands animal systems where reagents (e.g., antibodies and probes) are readily available and where turnover of individuals (breeding) and the occurrence of biological events (e.g., morphogenesis, disease development, injury repair, and aging) are rapid. Therefore, the study of animals with short development and life cycles (days to months) provides the best opportunities for detection and observation of the process under study. Common choices for fundamental research include *Drosophila melanogaster* (fruit fly), *Caenorhabditis elegans* (nematode worm), *Danio rerio* (zebra fish), and many varieties of *Mus musculus* (mouse), and *Rattus norvegicus* (rat). Technical methods to design and develop transgenic animals have greatly enabled the rigorous systemic and even focal conditional modulation of specific genes alone and in combination in these species, and have dramatically advanced the rate of fundamental biological discovery in the past decade. The sequencing of these genomes and the general homology of many biological processes across large evolutionary gaps has broadened the relevance of discoveries across species. However, in the case of studies on bone tissue, only bony vertebrates, fish, and higher vertebrates are specifically relevant.

Feasibility and bioactivity testing takes one step toward clinical translation, by asking, "Is this mechanism a possible therapeutic target?" and "Will modulation of this mechanism using this specific set of local or systemic means influence the development or progression of disease or repair without unacceptable toxicity?" Feasibility and bioactivity testing

generally includes assessment of biocompatibility, toxicity, screening for adverse reactions, and the capability of delivering a given device or agent in a manner in which it has a measurable and desirable effect.

The same models that are used to test feasibility are often used as screening systems for quality control by confirming bioactivity or performance of existing reagents or products and determine whether the methods of fabrication or processing are changing over time. Models used in this domain are generally designed to deliver the therapy or agent in a manner that closely approximates methods of delivery in a clinical setting (oral, IM, IV, tissue infusion, or open implantation), and to examine specific tissues or fluids that are most likely to be sensitive to change (e.g., blood, urine, and tissue). In the setting of an implant, the anatomic location and tissue at the site of implantation will generally match the type of tissue, if not the exact location, in which therapeutic use is expected. However, in the case of bone formation or repair, both subcutaneous, epimuscular, intramuscular sites and periosteal and intraosseous sites of implantation (both cranial and long bone) have been used.

Feasibility testing is almost always done in small mammals and specifically in mice and rats. Many standard models for the assessment of implant materials have been codified in standard protocol documents published by major standards and regulatory organizations, including the American Society for Testing and Materials (ASTM),<sup>16</sup> the International Standards Organization (ISO),<sup>17</sup> the United States Food and Drug Administration (FDA),<sup>18</sup> and the European Commission.<sup>19</sup> However, for many relevant strategies and biological processes (e.g., delivery of bioactive factors, cell transplantation, cell homing, and migration), existing models may not provide optimal or generally accepted tools for feasibility testing. As a result, considerable opportunity remains for the development of models for rapid *in vivo* feasibility assessment based on the function of cells and bioactive factors.

Like model systems used for fundamental discovery, models used for feasibility and bioactivity testing benefit from the use of inbred strains of mice and rats, where outcomes can be determined after relatively short periods of observation (days to weeks), where reagents (e.g., antibodies and probes) are readily available, and where the variation in radiographic, imaging, histological, or biochemical outcome between individuals is small (reducing the number of animals needed to achieve a statistically significant assessment). When evaluating implant materials, models enabling the assessment of multiple samples in a single animal subject are also preferred, both providing control for variation between animals and limiting the number of animals needed. All of these factors help limit the time, expense, and subject burden needed to complete a given body of research.

In some settings, feasibility studies must be advanced into a larger animal, such as a rabbit, dog, sheep, or goat. However, these settings are generally limited to just a few situations: (1) when the surgical procedure involved cannot be performed reproducibly in a smaller animal (e.g., spinal fusion procedures or tendon/rotator cuff repair procedures), (2) when the size of the implant or device under study exceeds the volume capacity of a smaller animal (e.g., assessment of an implant over 1–4 cm, depending on the tissue site), and, similarly, (3) when there is the need to model effects of large

diffusion distances or void volumes, as in the case of mass transport limitations (e.g., diffusion of oxygen) in the survival of transplanted cells.

Clinical modeling and efficacy prediction is also generally referred to as “preclinical animal testing.” In this setting, animals are used to test the questions, “Is this therapy, material, or method optimized for performance in the clinical setting in which it is intended?” or “Will this method perform as well or better than an existing standard therapy?” Animal models used to address questions in this domain are designed to create an environment that is as close as possible to the clinical setting in which a therapy will be used. Therefore, key criteria of these models and studies are to (1) deliver the therapy in the manner in which it will be delivered in a clinical setting; (2) utilize a site of delivery and/or assessment site that is as closely matched as possible to the setting(s) in which it will be used (anatomic site, anatomic size, and local tissue characteristics—presence of fat, muscle, scar, and vascular bed), (3) utilize surgical techniques (when applicable) that match or are most analogous to clinical methods; (4) utilize an animal that provides a metabolic background and physiological responsiveness comparable to humans, and (5) utilize a formulation of active agent that has the same composition, dose, release, retention, and degradation properties as the formulation that will be used clinically.

These criteria can be applied rigorously in settings evaluating synthetic and nonimmunogenic biomaterials or reagents. However, in some settings biological factors force some modifications in the last criterion. For example, when evaluating some bioactive active agents (e.g., growth factors such as bone morphogenetic proteins [BMPs]), large species-specific variations in efficacy and dose responsiveness may be present.<sup>20–31</sup> As a result, preclinical assessment in this setting can be complicated by the need to identify and utilize an animal species in which responsiveness is comparable to humans or to utilize a species-specific formulation that is modified to create an effect that is comparable in the model being used to the bioactivity expected in the clinical setting. In the setting where allograft tissue-derived materials are being assessed, immunological barriers make implantation of human tissues into animal subjects (a xenograft) an inappropriate model. As a result, assessment of allograft tissues in an animal model requires not that human allograft tissues be used, but that the methods of tissue procurement and processing are as closely matched to clinical methods used on human tissue as possible. Fidelity between the materials being assessed is therefore not based on standardized formulation and composition, but rather is based on the validateable presumption that composition of bone matrix from humans and other large animals will be altered similarly when identical processing methods are used.

The preclinical assessment of strategies utilizing autograft or allograft cells is similarly limited by immunological barriers that make transplantation of human cells into animals as xenografts inappropriate as a model for clinical application. As a result, specific methods of cell harvest and processing become the variable that can and should be modeled to the clinical standard. This relies on the validateable assumption that the starting composition and intrinsic biological potential of tissue-derived cell populations from large animal species (including progenitors and stem cells) is comparable to cell populations that may be harvested from human subjects and that identical

processing steps will result in comparable changes in composition and relative biological potential and performance.

Special challenges are presented, however, when the clinical cell processing or validation methods can only be applied to human cells, due to the need to use species-specific reagents (e.g., antibodies that do not cross react with the corresponding functional homolog in an appropriate animal or where no nonhuman homolog exists). In this case, preclinical studies might require use of a surrogate reagent or process that provides comparable processing effect to the missing reagent. Thereby, the variable that can be assessed in the preclinical setting becomes a process with a particular outcome (e.g., a comparable change in composition of the cell population), rather than exact method of processing that would be used clinically to achieve this end result.

Far more substantial challenges and risks are presented when cell processing involves *in vitro* culture expansion, rather than direct transplantation or immediate intraoperative processing. In this setting, species differences in optimal culture conditions (serum and growth factors requirements/responsiveness) confound the opportunity to directly apply validated human methods or to refine *in vitro* systems for a given species with the presumption that they would provide comparable effects on the selective proliferation of subsets of proliferative cells or on differentiation or long-term biological potential to those achieved by highly refined systems developed for human clinical application. Preclinical systems must also be established to assess the long-term fate of culture-expanded cells, and to detect and limit the potential for selection or development of clones with undesirable or potentially harmful biological properties during periods of rapid expansion outside of the normal systems of systemic immune surveillance.<sup>32,33</sup>

Some useful general guidelines have been published by the FDA relevant to the design of preclinical studies to assess cell therapy strategies.<sup>34</sup> Additional proactive attention to the development of a more rigorous system of nomenclature for the stem cell and progenitor cell populations that are the target of cell therapy development and of better defined standards and models for *in vitro* and *in vivo* are needed, and will greatly enable and accelerate the development of safe and effective cell therapy strategies.

### Biological Principles and Technical Considerations in Choosing an Animal Model

The design and selection of animal models for clinical translation is intimately related to the therapeutic modality that is being tested. A review of potential modalities of therapy is beyond the scope of this paper. Several recent reviews of this topic are available.<sup>35–39</sup> Overall, the tools and materials that may be applied to these settings include scaffold materials (e.g., allograft bone, synthetic polymers, and calcium phosphate ceramics), cell sources (autogenous bone, autogenous marrow, local tissue, and culture-expanded autograft of allograft cells with or without genetic modification), bioactive factors (e.g., BMPs, vascular endothelial growth factors, platelet-derived growth factors, epidermal growth factor, and parathyroid hormone [PTH]), and mechanical/biophysical modulators (cast/brace immobilization; internal or external fixation; and electrical, magnetic, mechanical, or ultrasound stimulation).

A useful conceptual paradigm is to recognize that virtually all therapeutic modalities can be categorized based on one or more of the following five domains of biological activity or function<sup>1</sup>:

**Osteogenesis** the process by which osteogenic stem cells and progenitors create new bone tissue through processes of homing, activation, proliferation, migration, differentiation, and survival. This includes all modes of cellular therapy, that is, the homing or harvest, processing, and transplantation of osteogenic cells.

**Osteoconduction**, that is, scaffold functions preservation of a defined tissue volume in a manner that prevents the encroachment of adjacent tissues and that promotes the attachment, migration, distribution, and survival of osteogenic cells within a defined tissue volume.

**Osteoinduction** traditionally defined as the process by which soluble or matrix-bound signals interact with local cells (progenitors or nonprogenitors) to initiate a cascade of cellular events that change the fate of local uncommitted stem cells or progenitors toward an osteoblastic phenotype.

**Mass transport**, that is, the general process of flux and exchange of chemical modalities through tissue by convection (physical and mass movement along pressure gradients as in vascular channels or in extracellular fluid spaces exposed to deformation via movement or external deformation), diffusion (passive migration of chemical species along concentration gradients of sub-micron to millimeter scale), or active pumps (usually acting only across membranes at short distances). Mass transport modalities, would therefore include modalities to preserve or enhance vascular transport (including vascularized tissue grafts) and means to enhance revascularization through angiogenesis.

**Biophysical effects** generally grouping modalities of mechanical forces (strain, shear, compression, and pressure), temperature, and electrical and/or magnetic field effects.

In general, every living system in which bone exists (fish to mammals) will be influenced by these variables. However, variables of physical size, anatomy, and species-specific histology and physiology make some models better suited for investigation of individual domains than others. For example, in the domain of osteoconductivity, screening of a given scaffold as a bulk material with respect to variables of biocompatibility, surface osteoconduction, toxicity, and degradation rate can be performed in small defects and using solid discs, screws, or rods using bone defects of 2–5 mm in maximal dimension and as thin as 1 mm in size (generally in mice, rats, and rabbits). In contrast, evaluating a porous scaffold material, in a setting where mass transport is the primary variable and the question under study is the capacity of a porous scaffold to induce the ingrowth of new blood vessels as a delivery system for a bioactive factor enabling the survival cells across a gradient of profound hypoxia within a wound environment, requires work in a larger defect measuring 1–5 cm in maximal dimension but no thinner than 5–10 mm (generally dog, sheep, and goat).

In the domain of osteogenesis, rodents have provided an effective setting for screening for evidence of stem cell and

progenitor cell homing to sites of bone repair,<sup>40,41</sup> evaluation of the differential effects of marrow-derived and periosteal-derived cell populations,<sup>42</sup> and in screening for the effects of cell transplantation across major and minor histocompatibility barriers using nonvascularized,<sup>43</sup> vascularized,<sup>44</sup> and even whole limb transplantation.<sup>45</sup> These studies are greatly enabled by means for marking and tracking cell progeny from different sources over time (discussed in more detail below).

However, rodent models begin to fail when questions evolve toward clinical application. In addressing questions of cell and tissue harvest methods and methods for processing autogenous cells for transplantation, rodent models are not well suited. The anatomy and composition of autogenous bone and marrow in rodents provides a dearth of cancellous trabecular bone (rodent long bone are primarily cylinders with little metaphyseal cancellous bone except immediately adjacent to the physis). As a result, autograft controls in rodent inevitably represent a mixture of bone marrow with minced cortical bone and periosteum; this composition is not comparable to the purely cancellous bone grafts used clinically and available in dog, goat, and sheep models. Rodent-derived marrow cells are also intrinsically different in biological performance than marrow from large animals and humans. When marrow is irrigated from rodent long bone (the most common method of harvest) the fraction of osteogenic colony forming units (CFU) is only 10–20% of all fibroblastic CFU.<sup>46</sup> In contrast, in human marrow aspirates, over 90% of fibroblastic CFU colonies are osteogenic (i.e., can be classified as osteogenic CFU).<sup>47–49</sup> Moreover, in addressing questions related to the limitations of mass transport and hypoxia on the survival of transplanted cells in a clinically relevant setting, it is necessary to evaluate defects in which diffusion distances are clinically relevant, in general 3–5 mm or more from the nearest vascular bed (i.e., minimum diameter or thickness of 6–10 mm). Defects in this range can only be accommodated in large animals (dogs, sheep, goats, and pigs). A more detailed discussion of animal selection in the domain of translational models is addressed below.

New cell therapy strategies that involve the local recruiting or homing of autogenous or engineered cells to a site of injury or therapeutic interventions have recently increased the need to rigorously define and track the fate of cells that may be implanted, injected, or homed from systemic circulation. In this domain, mouse models have gained renewed importance. Tracking of cells from a defined source and their progeny has been most effective using green fluorescence protein (or engineered variants) as a constitutive or conditionally expressed marker. Mouse calvarial defects<sup>50</sup> and fibular fracture repair models<sup>41</sup> have been used effectively to define the process of progenitor cell homing from systemic circulation.

### Practical Issues in Design and Selection of Animal Models for Clinical Translation and Preclinical Testing

A myriad of variables must be rationally defined to insure that the assessment achieved using the model will be most relevant to the clinical domain of interest. Subsequently, as many variables as possible must be controlled to minimize random effects and to make variation in outcome as sensi-

tive as possible to the effects of test variables and to minimize the number of animal subjects needed to achieve statistical power. Among the many variables are animal subspecies; animal subject inclusion criteria (age, sex, partum, and gonadal and estrus/lactation status); nutritional status; diet; exercise/activity regime; animal temperament (often a function of species and vendor); anesthetic, pharmacologic, and pain management; the setting of bone repair/regeneration (fracture, osteotomy, and defect); anatomic location (bone and site); use of fixation (bracing, internal, and external); the time-points for assessment; the relevant endpoints of outcomes to assess; and the means for assessment (radiographic, histological, biochemical/molecular, and mechanical). Further, within the domain of a repair/regeneration setting are further variables, such as local tissue environment (preservation or removal of periosteum or local marrow, and the character of adjacent tissue, i.e., fat, muscle, and fibrous tissue or scar). In the setting of fracture, fracture location and pattern must be defined using a consistent mechanism of injury.<sup>51,52</sup> In the case of osteotomy, the location and geometry of the osteotomy as well as the means by which it is created must be defined. Large differences have been shown between surgical techniques (corticotomy vs. osteotomy),<sup>53</sup> irrigation during osteotomy,<sup>54,55</sup> use of sharp versus dull instruments, reaming with or without a tourniquet,<sup>56–58</sup> and the management of periosteum and local soft tissues.<sup>59,60</sup> The importance of defining and following precise and reproducible and standardized protocols that define each of these variables cannot be understated, not only to enable objective assessments within a given lab or project, but also to enable objective comparisons between laboratories.<sup>61</sup>

Given the large opportunity for variation among so many variables, the selection of the most appropriate model to address a given scientific question has been principally a question of judgment and opinion, and will remain so for at least the next few years. However, the goals and principles of defining the conditions in each model are generally the same: (1) limit variation from animal to animal as much as possible, (2) define methods for assessment that are sensitive to change in the most important outcome (e.g., bone formation, bone bridging, remodeling, and revascularization), (3) utilize treatment conditions/materials that most closely match the material or treatment that will be used clinically, and (4) utilize a biological tissue bed that most closely matches the tissue bed that will be present in a clinical setting.

Every setting in which materials are tested seeks to achieve these goals, but no model environment can maximize all of these variables simultaneously. Small uniform defects in animals of uniform age, sex, and genetic background, which maximize the first two goals, fall miserably short on the third, matching the clinical conditions of a wound site. This is particularly true regarding the variables of mass transport environment (e.g., oxygen diffusion/hypoxia, concentrations/gradients of signaling molecules, and revascularization rate) and progenitor cell kinetics (i.e., progenitor concentration/distribution, survival of local or transplanted progenitors, or progenitor cell homing or migration events), which are highly dependent on wound size.<sup>2,3</sup> At the other extreme, the gold standard of a human clinical trial will, by definition, exactly match the biological tissue bed in the clinical setting, and the clinical material (Goals 3 and 4) fails miserably to limit variation (Goal 1) and enables only limited radiographic and



histological assessment (Goal 2). Some large sources of clinical variation can be excluded by setting age, sex, disease, body mass index, site, and other exclusion criteria, as is common in clinical studies. However, clinical trials of bone repair and regeneration inevitably include subjects with large variation in systemic biology, including genetic background (including receptor phenotypes),<sup>62–64</sup> immunological sensitivities, endocrine status, nutritional status, comorbidities, and pharmacological effects. They are also associated with large differences in local biology at a given site of bone repair, including defect size and shape, local vascularity, the health and composition of local tissue (marrow, bone fat, muscle, and fascia), the presence of scar (prior surgery, trauma, and radiation), or biophysical environment (loading, shear, and strain).

The scope of this review precludes detailed discussion of the decision-making process linked to the many variables involved in a given model. The following sections provide a very short overview, drawing heavily on information that is summarized well in several recent reviews.<sup>36,65–72</sup>

### Selection of Animal Species

A wide variety of mammalian species are used in bone research. Figure 2 illustrates the differences in size, shape, and internal architecture of bone among 10 mammalian species that are commonly used for bone repair and regeneration research. Figure 3 compares cortical and trabecular microstructures of their distal femur samples. In general, preclinical translational testing is performed in large skeletally mature animals, rather than rodents or rabbits. Dog, goat, sheep, and pig are the most utilized species.<sup>65</sup> The use of these animals provides a skeletal biological environment that is not undergoing ongoing growth or modeling (a lifelong process in rodents, which do not fuse their growth plates). The use of large quadrupeds also provides the opportunity to utilize autogenous cancellous bone as a control or gold standard for contemporary bone grafting. Cancellous bone can be harvested from the proximal humerus (the largest bone in quadrupeds) using a small cortical window in quantities and in a consistency that closely matches cancellous hematopoietic bone and

marrow from the human iliac crest. Large animals also allow the use of fracture, osteotomy, and defect sites as well as methods of internal and external fixation that more closely match those used in clinical settings.

Nonhuman primates (NHPs), African green monkeys (*Cercopithecus aethiops*), Rhesus macaque (*Macaca mulatta*), and baboon (*Papio hamadryas*) have been used in studies of bone repair. The use of NHPs adds substantially to the cost of research and is associated with some cultural and ethics questions. The primary rationale for NHPs is the opportunity to match the genetic background and therefore the biological responsiveness of the model as closely as possible to humans. It has been assumed that this will provide the most predictive model for immunological and biological response, particularly in the setting of delivery of human peptide growth factors such as BMPs. However, the variation in response between primate species can be as great as or greater than variation between humans and quadrupeds. Baboons, for example, are reported to be hypersensitive to BMPs.<sup>20,21,73,74</sup>

One disadvantage of NHP models, other than baboon, is that they are anatomically much smaller in size than other large animals. The adult Rhesus weighs only 6.5–12 kg (male), and has a femur measuring 16.5 cm in length and 1.25 cm in mid shaft diameter (as compared to a coon hound dog measuring 20 cm in length and 2.5–3 cm midshaft diameter). This compromises the opportunity to match the defect volumes and fixation methods available in other models.

Therefore, although these primate models are conceptually appealing, there is at this time no definitive consensus nor compelling need to propose that the preclinical assessment of new technologies for bone repair and regeneration must pass through a NHP model. In the future, *in vitro* screening of biomaterials and active agents and direct comparison of the *in vitro* response of human subject animal cells to a bioactive agent may become an appropriate step to confirm that a given animal model provides an appropriate biological background for assessment.


O'Loughlin *et al.*<sup>65</sup> recently summarized the reported use of animal models for study of fracture repair in long bones based on articles published in six orthopaedic journals over a 10-year period. These papers included fractures without



**FIG. 2.** Comparison of femoral size and anatomy among animal species commonly used for bone regeneration research. Anterior view of left femurs of adult animals (from left to right): mouse, rat, rabbit, dog, goat, sheep, pig, South African monkey, rhesus, baboon, and human. Color images available online at [www.liebertonline.com/ten](http://www.liebertonline.com/ten).



**FIG. 3.** Comparison of cortical and trabecular microstructures. MicroCT scans of distal femurs are depicted. (A) The pattern and distribution of cancellous bone in the distal femur and metaphysis. MicroCT resolution: 45  $\mu\text{m}$  for all bones except for mouse and rat, which are scanned at 27  $\mu\text{m}$ . (B) Cross section of the cortical diaphysis along the plane indicated by the red line in (A). (C) Cancellous bone from the medial femoral condyle, illustrating trabecular architecture. Dimensions of the trabecular cube: 5 $\times$ 5 $\times$ 5 mm (0.125 cm<sup>3</sup>). Color images available online at [www.liebertonline.com/ten](http://www.liebertonline.com/ten).



gaps, noncritical-sized gap defects (which would generally heal spontaneously during the lifetime of the animal), and critical defects, which will not heal without intervention. The relative use in this domain in order of frequency was rat 38%, rabbit 19%, mouse 13%, sheep 11%, dog 9%, goat 4%, and other 4%. Closed models of fracture repair involving a blunt guillotine mechanism<sup>75</sup> have been used in approximately 40% of studies involving the rat and mouse. However, almost all studies in larger animals utilize open defects. Internal or external fixation has been used with roughly equal frequency. Roughly 20% of research studies using mice, rats, and rabbits reported no use of fixation other than external immobilization (generally ulna and fibula models). However, immobilization alone was used in few models in larger animals.

Utilization of animal models in the spine has not been reviewed in similar detail. Mouse and rat models are generally avoided because of their small anatomic size. The rabbit intertransverse posterior fusion model without internal fixation<sup>76–83</sup> has been a common starting point. Rabbit intervertebral fusion is not utilized. The rabbit intervertebral space has a marked tendency for rapid degeneration and even spontaneous fusion following relatively minor trauma to the annulus.<sup>84</sup> Canine models for posterior fusion have been described with<sup>85–92</sup> and without<sup>85,87</sup> internal fixation. Goat,<sup>93–97</sup> sheep,<sup>98–103</sup> and pig<sup>104–110</sup> models allow more opportunity for internal fixation anteriorly or posteriorly. However, it must be noted the horizontal loading of the lumbar spine in quadrupeds (all animal models including NHPs) does not reproduce upright posture of bipedal humans with respect to axial compression and rotational loading in the human lumbar spine. This incongruity in the mechanical loading of spine models can be less profound in the cervical spine of sheep and goats, where a relatively upright posture have been exploited effectively as models of human cervical bone grafting.<sup>111–115</sup> Fusion models in NHPs are generally limited to the lumbar spine and performed both anteriorly<sup>116–119</sup> and posteriorly,<sup>120,121</sup> and with<sup>116,122</sup> and without<sup>120</sup> internal fixation.

Evaluation of biomaterials and surgical strategies for craniofacial applications has appropriately utilized many animal models, including calvarial defects,<sup>71,123–145</sup> maxillary sinus

augmentation,<sup>146–155</sup> alveolar ridge augmentation,<sup>156–171</sup> and mandibular defects.<sup>172–182</sup>

In addition to defining the genetic background, the choice of animal species also establishes boundary conditions to the work that can be performed in many other dimensions, including the range of possible defect sizes, options for reagents (cells, growth factors, antibodies, and probes), parameters of defect fixation and mechanics, and even the possible duration of experiments (dependent upon life span). Table 1 provides an overview of the key features of various animal groups and species.<sup>183–189</sup>

Mimicking the underlying bone biology of the human clinical setting is one of the principle goals of selecting a given animal. The biology of these species differs in several important respects. For example, rodents continue to model (i.e., grow and reshape) their skeleton throughout their lives. Growth plates remain open. In addition, the trabecular bone content of rodent bone is limited, even in metaphysis of long bones. Moreover, Haversian remodeling by tunneling osteoclasts does not occur in rodents. All of these factors are significant negatives when considering rodents as appropriate models of human bone biology. In contrast, rabbits (i.e., lagomorphs no longer classified as rodents) have both larger and relatively more trabecular bone mass that exhibits Haversian remodeling. However, rabbits have very fatty (oily) marrow that is distinctly different in physical properties than human marrow, making them an undesirable choice as a model for autogenous bone and marrow harvesting, processing, or transplantation. Rabbits also are notoriously sensitive to glucocorticoid stimulation, which results in profound intraosseous fatty hypertrophy and secondary avascular necrosis of bone.<sup>190–192</sup>

Bone composition and biology of dog, sheep, goat, and pig are very similar to those of humans. Detailed reviews of the robust literature comparing bone structure, composition, and biology in these animals<sup>68,70</sup> identify modest differences in cancellous and cortical bone density at various sites, differences in response to ovariectomy and dietary calcium restriction, magnitude of sexual dimorphism, the age at which peak bone mass is achieved, and the rate and extent to which Haversian remodeling replaces plexiform lamellar bone in the

TABLE 1. OVERVIEW OF THE KEY FEATURES OF VARIOUS ANIMAL GROUPS AND SPECIES

	Mouse		Rat		Rabbit	Dog	Goat	Sheep	Pig	South African monkey	Rhesus	Baboon	Human
Common name or type	Nude mouse/ house mouse		Rat/Sprague Dawley rat		New Zealand rabbit	Beagle, coonhound, or mongrel dog	Spanish goat/South African goat	Domestic sheep	Domestic pig	Mona monkey	Rhesus macaques	Hamadryas baboon	Human
Scientific name	<i>Mus musculus</i>		<i>Rattus norvegicus/ rattus</i>		<i>Oryctolagus cuniculus</i>	<i>Canis familiaris</i>	<i>Capra hircus</i>	<i>Ovis aries</i>	<i>Sus scrofa</i>	<i>Cercopithecus mona</i>	<i>Macaca nemestrina</i>	<i>Papio hamadryas</i>	<i>Homo sapien</i>
Adult weight	12–30 g		70–300 g		1.50–2.50 kg	Beagle: 8.2–16 kg Coon-hound: 32–40 kg	45 kg avg	110 kg	50–350 kg	Male: 5 kg Female: 4 kg	Male: 6.5–12 kg Female: 5.5 kg avg	Male: 21.5 kg Female: 9.4 kg	76–83 kg
Life span	2 years		4 years		9 years	20 years	15 years	10–12 years	10 years	20–30 years	30 years	37 years	50–80 years
Age of skeletal maturity	Continuous growth		Continuous growth		10–11 months	12–18 months	3 years	15–18 months	12–14 months	Not available	7 years	5 years	16–18 years
Age of sexual maturity	5–7 weeks		3–5 months		8 months	6–12 months	5–10 months	6–8 months	9 months	2–5 years	2.5–4 years	Male: 4.8–6.8 years Female 4.3 years	12–18 years
										Sexual dimorphism only in size		Highly sexually dimorphic	years

cortex of long bone. However, these points of variation do not provide evidence that any one of these animals provides a better match for human bone biology than the other. As a result, all of these animals provide excellent options. As a result, considerations of expense, local access, temperament, ease of husbandry, personal or institutional experience, the need or desire to reproduce an established precedent, and unique anatomic considerations become the legitimate drivers of decisions between these options. Pigs tend to be least used,<sup>65</sup> likely due to difficult temperament, anatomically short and thick long bones, and large size. The short bones do not allow for large gap defects because adequate fixation is difficult to achieve. Minipigs are more manageable, but may also be less desirable due to concern that these genetic dwarfs may be less biologically similar to humans than common domestic animals. Dogs are used most in North America both due to a rich background of prior experience, ease of husbandry, and accessibility. Purpose-bred beagles (a relatively small dog) or coon hounds (a large dog) provide reproducibility not offered by more heterogeneous mongrel dogs. A robust literature characterizing canine models supports continued preferential use of dogs in many settings, particularly in bone marrow biology and transplantation immunology.<sup>193–206</sup> The use of dogs is being challenged, however, by social concerns regarding the dog as a companion animal. Sheep are long boned, and allow use of many systems of internal fixation used in human clinical practice. Sheep are readily available and docile, but can be frail and less resilient, particularly when not in a group. Goats, similar in size and skeletal anatomy to sheep, have a thinner coat and less muscular bulk, and are more tolerant of stress and isolation. Goats are also becoming more available in the United States, making them an increasingly viable alternative for bone research.

NHPs are sometimes held up as the model of choice for prediction of clinical performance for bone repair and regeneration methods. This supposition is based on arguments of evolutionary proximity and similar structural anatomic, endocrine, digestive, and dietary features and immunology. However, it is difficult to justify a view that the use of NHPs should be proposed as a gold standard for work in bone repair and regeneration. Defect size is an important limitation in the African Green Monkey and Rhesus. Of the three common NHP species, only the baboon approaches the skeletal size range that humans share with large canines, sheep, and goats. NHP species exhibit profound sexual dimorphism (males larger than females) that is far greater than humans. Moreover, there is heterogeneity in the biological response among NHPs that diminishes the argument that evolutionary proximity necessarily equates to improved clinical prediction. For example, in preclinical studies of BMPs the baboon has been reported to be hypersensitive to BMPs and to require doses of BMPs substantially lower than Rhesus to induce the same effect.<sup>20,21,73,74</sup> NHPs are very expensive and present husbandry challenges that preclude models involving intensive wound assessment, management, or immobilization. In addition, although NHPs do not have companion animal status, arguments of perceived evolutionary affiliation raise social and ethics questions related to increasing their use in research. Most important, however, methods that work well in NHPs tend to work well in other large animals and vice versa. As a result, although exceptions must be considered, there is a lack

of direct evidence that NHP models are systematically or consistently superior to other large animal model as a means of objective assessment comparison between implanted devices, cell transplantation strategies, or growth factor delivery systems, with respect to biological mechanism or prediction of either relative or absolute clinical performance than other large animal models.

### **Systemic Factors—Age, Sex, Endocrine, and Pharmacological Status**

Systemic variables are well-established variables having important effects on the outcome of bone repair and regeneration. This has implications both on the clinical relevance and on the sensitivity and responsiveness of a given model. Many studies have demonstrated effects of endocrine status, including estrogens, androgens, thyroid hormone, PTH, PTH-related protein (PTHrP), and glucocorticoids, in settings of intrinsic cyclic variation (e.g., estrous cycle), surgical ablation, genotypic variation, or pharmacological administration.<sup>70,207</sup> Therefore, the genetic background and endocrine status become important to define and control.

Age has also been identified as a key systemic variable influencing the character and outcome of bone repair and regeneration, though these studies have generally been limited to date to small animal models.<sup>207,208</sup> In large animals, expense considerations tend to drive research to be performed using young animals soon after they reach skeletal maturity, due to the increased cost of raising purpose-bred animals to an advanced age. The sensitivity of young animals as models for detection of the therapeutic efficacy or toxicity associated with some therapies is limited, because young animals and humans may not express deficiencies in stem cell biology, angiogenesis, growth factor synthesis, or signal transduction that may become manifest later in life. Therefore, near exclusive assessment of bone repair and regeneration strategies in young healthy animals may result in a collective distortion of outcome. On one hand, the base level of performance of a given strategy is likely to be overestimated relative to the clinical setting. On the other hand, exclusive use of young animals may also underestimate the incremental effect of adding adjuvant methods directed at age-related deficiencies and even the characterization of dose response effects and the detection of toxicity associated with some therapies. An increased use of aged animals is one of the possible means to enhance to refine existing animal models. Aged rodents can be purchased from certified vendors and the National Institute on Aging ([www.nia.nih.gov/Research Information/Scientific Resources/](http://www.nia.nih.gov/Research%20Information/Scientific%20Resources/)). In addition, purpose-bred animals retired from breeding stock (usually females) are a potential cost-effective source of aged large animals.

### **Local Biological Factors—Defect Size and Type**

Fractures in animals and humans generally heal with a high frequency of success. Failure of repair generally occurs only in settings where one or more complicating factors are present, including a defect or gap in bone (caused by either tissue loss or distraction maintained by internal or external fixation), local tissue loss (particularly periosteal tissue or local intramedullary marrow), interposition of soft tissue (fat, muscle, and tendon), local osteonecrosis or soft tissue necrosis, local infection, extensive scarring, excessive mechanical mo-

tion, biological compromise resulting from dietary deficiency, endocrinopathy (especially parathyroid, thyroid, and adrenal abnormalities), pharmacological effects (e.g., non-steroidal anti-inflammatory drug (NSAIDs), chemotherapy, and glucocorticoid use), and radiological effects (local radiation therapy).<sup>209</sup>

In the design of a clinically relevant animal model system, each of these variables can be and have been used as means to “elevate the bar” and increase the biological challenge to bone tissue regeneration and the extent that treatment would be required to achieve bone repair. In the clinical setting, of course, no one factor is present. It is always a combination of these factors that determines the biological challenge and the risk of treatment failure. However, of all these possible variables that can be used, a defect or gap in bone is both most easily standardized. Defects can generally be divided into cylindrical defects, which can be reproducibly created using a trephine or drill, and segmental defects, created using a transactional saw. Hemicortical defects have been used, but less frequently.<sup>122</sup>

Critical-sized segmental bone defects have become the mainstay of translational models to evaluate and compare bone repair strategies. In 2009 the ASTM published the *Standard Guide for Preclinical In Vivo Evaluation in Critical Sized Segmental Bone Defects* (F2721-09),<sup>210</sup> which serves as an excellent resource. Critical defects are defined as “a defect that will not heal without intervention.” The femur and tibial diaphysis tend to be used most often, but require internal fixation (rod, plate, or external fixation). Radius, ulna, and metatarsal models have also been used, and can be used without fixation in many settings. The actual defect size that is necessary to preclude healing without intervention varies between species and anatomic sites. However, as a rule of thumb, a segmental defect in the diaphysis of a long bone that is 1.5–2 times the diameter of the bone involved will result in a nonhealing defect.

Segmental defects are readily created using standardized methods. Although these models are considered to be highly reproducible, there are many sources of minor variation that can influence outcome, and can contribute to systematic differences between the biological environment of one model compared to another, and differences with respect to the clinical environment. Some of these sources of variation are enumerated below.

The biological environment or envelope of fresh or acute segmental bone defects is generally bounded by at the ends by normal cortical diaphyseal bone (including periosteum, endosteum, and bone marrow), and surrounded by normal muscle, mixed with some fat and remnants of fibrous muscle insertion sites to the excised bone. Their uniform dimensions and defined anatomic location make them readily assessable with respect to new bone formation and revascularization using radiographic or histological methods. Mechanical outcome can be assessed using standardized measurement of torque and bending stiffness and loading to failure. Sampling for assessment of biochemical or molecular markers can also be anatomically and geometrically defined.

Cylindrical defects in the frontal or parietal bone of mouse,<sup>132,211,212</sup> rat,<sup>213–215</sup> and rabbit<sup>134,216,217</sup> have in many ways been the primary screening tools or point of entry for the assessment of many biomaterials. Like segmental defects, cylindrical defects have the value of being reproducible both in size and local anatomy. They also generally provide a


stable mechanical environment that does not require internal fixation, thereby removing effects of stress shielding and any compromise of radiographic assessment associated with metallic implants used for internal fixation.

In the setting of cranial defects, the tissue envelope that defines the biological setting of bone repair is considered to be relatively reproducible. In every defect, the vascular dura floating on intracranial fluid is always at the base. Cortical bone sandwiching cancellous bone and marrow is distributed circumferentially around the rim at a generally uniform thickness. Cranial sutures are generally avoided. This allows highly reproducible positioning of an implant that is precisely matched to the defect, usually without internal fixation. The tissue overlying the implant site is dependent on surgical technique and may be defined by retained periosteum, Galen’s fascia, subcutaneous fat, or dermis and skin. In the setting of an ungrafted defect, dura and overlying soft tissue will encroach into the defect and compromise bone regeneration, making this model very responsive to the performance of scaffold materials, even if they simply provide the mechanical integrity needed to resist soft tissue encroachment and preserve the space for bone formation.

In the setting of cylindrical defects in long bones, the tissue envelope that defines the biological setting of bone repair is again highly defined.<sup>218–229</sup> The composition of the defect opening generally includes periosteum, cortical bone, and endosteum. After closure, the opening of the defect is bounded by overlying muscle or fat. The base of the defect may be cancellous bone and marrow, cortical bone, or muscle/fat, depending on defect length and orientation within the long bone. The tissue quality within the defect—particularly, periosteum, cancellous bone, and bone marrow—will depend strongly on the anatomic site, species, and age. In general, defects in the metaphysis of young large animals will be comprised of highly vascular hematopoietic marrow. However, marrow in defects in the diaphysis will generally be fatty or yellow marrow, which is still vascular, but far less cellular. Advancing age in humans and animals will also increase the ratio of fatty to hematopoietic marrow, changing the biological environment of the graft site. Soft tissue encroachment does not compromise bone formation in most cylindrical defects, so mechanical resistance to encroachment is not necessary for success in these models. Regardless, cylindrical defects can be very sensitive to detecting differences in efficacy between osteoconductive scaffold materials as well as the effects of bioactive factors and cell transplantation.

The uniform radial geometry of cylindrical defects also provides the potential for control and modeling of biological gradients relevant to bone regeneration. Due to the pattern of diffusion and vascular ingrowth that must be oriented from the periphery to the center of the defect, cylindrical defects are particularly well suited for time-oriented studies of mass transport (e.g., the influence of diffusion, cellular metabolic demand, local oxygen delivery or generation, or gradients in the delivery of bioactive factors); the degradation rate of implants; cell transplantation (survival and migration); and variables modulating the rate of bone or tissue ingrowth or vascular invasion into an implant.

The canine femoral multidefect model (CFMD) introduced by Takigami *et al.*<sup>218</sup> is one example of a refined cylindrical defect model in a large animal that enables evaluation of variables of metabolic demand, mass transport, and



**FIG. 4.** (A) Revascularization in the canine femoral multi-defect model. (I) Four defects are drilled 10 mm diameter and 15 mm deep. (II) Illustrates the change in oxygen tension at the center of the defect after grafting using demineralized cancellous bone powder (DBMP). Note the initial drop in oxygen tension (days 0–3) as the oxygen sequestered in the initial hematoma is consumed. Oxygen tension remained very low to undetectable until day 12, as revascularization reached the center. (III) Bone formation is illustrated throughout the circular defect at the center of the graft site. (IV) New bone, mixed with unresorbed DBMP, is shown at the site of the tip of the oxygen tension probe. (B) Quantitative assessment of bone formation in the CFMD model is provided using microCT in units of percentage of mineralized bone tissue by volume. The pattern and extent of bone formation in each defect is assessed quantitatively using microCT. A sagittal reconstruction (above) shows the position of a defect and an optional snap fit cap. Percent bone volume is calculated from microCT data and projected in a two-dimensional plot illustrating the pattern and density of bone formation in each defect. Color images available online at [www.liebertonline.com/ten](http://www.liebertonline.com/ten).

revascularization in large defects (Fig. 4). In contrast to most large animal models in which only one graft site can be created per animal, the CFMD model provides four 10-mm-diameter and 15-mm-long defects per animal, enabling intrasubject comparison of materials or therapeutic strategies. These defects are of sufficient size that the biological environment in the interior of the defect is characterized by profound hypoxia, a key feature of clinical defects that is a limiting factor in cell survival and transplantation. Both bone formation and revascularization within the defect occur through a process of ingrowth that has a radially oriented “outside in” pattern that can be readily measured and characterized using microCT or histological methods. The importance of achieving a defect size in which diffusion becomes a limiting factor is particularly important when working with cells that rely upon diffusion for survival and with delivery of bioactive factors that must be distributed by a diffusion gradient. Diffusion rapidly becomes inefficient as

defect size increases. Further, as defect size increases, the defect surface area increases proportionally to the radius of the defect; however, defect volume increases proportionally by the square of the radius. The biological environment in the CFMD model crosses this threshold (Fig. 4A), and is markedly different from that in small defects in which the distance from the edge of the defect to the center of the defect is less than 3 mm (e.g., mouse and rat defects). In small defects, although oxygen tension may fall, cell survival is possible throughout the defect, supported by diffusion of oxygen and nutrients from the periphery. Similarly, in small defects the diffusion gradients of implanted bioactive factors are short, enabling dosing nearer the physiological range.<sup>1</sup>

#### Need for Standardization of Animal Models

The rational selection and use of animal models in all domains of use, from discovery, to feasibility testing, to

preclinical modeling, depends on reproducibility, sensitivity, specificity, biomechanical, and biological relevance. An animal model must provide the same or similar results in repeated experiments in the same lab and in identical experiments in different labs (reproducibility). Further, such models must enable detectable differences in outcome based on change in a particular test variable (sensitivity), as well as allow experimental design that isolates single independent variables for assessment (specificity). Defining reproducible methods for surgical and nonsurgical management and reproducible, sensitive, and specific means of documenting outcome using quantitative metrics (e.g., physical assessment, imaging, biochemistry, histology, and biomechanics) is absolutely essential in this process.<sup>61</sup> However, this is not an easy process. Living systems, particularly large animals, are complex and prone to substantial random variation. Moreover, outcome in each subject is subject to variation from multiple sources, which include but are not limited to the effect of the operator implementing an intervention (skills, and minor variation in technique), the animal (species, subspecies, genetics/epigenetics, temperament, age, sex, and systemic and local effects), experimental variables (e.g., material, dose, composition, activity, and interactions between these), environmental effects (facility protocols, and effects of housing, diet, and activity), and observer (skills, practice, and bias) or detection/observation method (sensitivity and specificity), as well as random effects.

At the level of individual laboratories, standardization is accomplished through rigorous documentation of standard operating procedures and through the use of hands-on training methods to pass operating techniques from one operator to the next. Standardization among laboratories is most often accomplished through transfer of protocols in peer-reviewed publications. However, published materials are often limited in communicating new or refined surgical as well as processing techniques. As a result, sharing of formal protocols including detailed descriptions of technique and staged photographs is often preferable. In many cases, important details are best communicated through direct personal interaction, and even a site visit to an experienced laboratory is necessary to enable hands-on experience as an operator or observer.

Overall, these methods for standardization within and between laboratories are highly variable. This fact likely leads to a high degree of variation within the reported literature, and within and between laboratories, even when nominally using the same model.

On a national scale, the ASTM has become increasingly active in developing guidelines and standards related to the use of animal models. The ASTM Subcommittee on Medical and Surgical Materials and Devices (F-04) has published several useful and generalizable standards that impact on the field of bone tissue engineering (Table 2). Of these, ASTM F2721-09, updated in 2009,<sup>210</sup> *Standard Guide for Preclinical In Vivo Evaluation in Critical Sized Segmental Bone Defects*, is of particular relevance to this review.

The ISO-published standard ISO-10993 also provides a series of standards for preclinical assessment of medical devices (Table 3). In particular, ISO 10993-6, "International Standards for Biological Evaluation of Medical Devices,"<sup>230</sup> provides excellent guidelines for the selection criteria for choosing an appropriate animal model for evaluation of biocompatibility.

TABLE 2. KEY AMERICAN SOCIETY FOR TESTING AND MATERIALS STANDARDS RELATED TO BONE TISSUE ENGINEERING

<i>ASTM standards</i>	<i>Description</i>
F04.04	Division IV TEMP
F04.05	Computer-assisted orthopedic surgical systems
F04.11	Polymeric materials
F04.12	Metallurgical materials
F04.13	Ceramic materials
F04.15	Material test methods
F04.16	Biocompatibility test methods
F04.21	Osteosynthesis
F04.22	Arthroplasty
F04.25	Spinal devices
F04.33	Medical/surgical instruments
F04.41	Classification and terminology for TEMPs
F04.42	Biomaterials and biomolecules for TEMPs
F04.43	Cells and tissue-engineered constructs for TEMPs
F04.44	Assessment for TEMPs
F04.46	Cell signaling

ASTM, American Society for Testing and Materials; TEMPs, tissue engineered medical products.

### The Missing Links Between Preclinical and Clinical Performance

The development, use, and interpretation of data from preclinical animal models remain a complex challenge and an imperfect science. Available animal models are deficient in predicting clinical performance in several domains: underestimation of variation in clinical response, overestimation of performance, and insensitivity to incremental improvement.

Underestimation of clinical variation in outcome is, of course, predictable and expected. Limiting variation is a desirable, if not necessary, feature of a useful model when testing feasibility and variation in formulation. However, this can be a liability in clinical translation. The local biological environment in clinical settings in which bone tissue engineering and regenerative medicine strategies are applied are far more variable than in available animal models. The systemic biology in the clinical setting is also far more variable than in animal models both in age and in the addition of comorbid conditions (e.g., diabetes, tobacco use, nutritional status, obesity, osteoporosis, and estrogen/androgen status). As a result, both absolute and relative performance in the clinic may often fall away from preclinical predictions when these extra factors are added, alone, and in combination.

Overestimation of clinical performance is also a predictable development, although it was not necessarily true at the time when the concept of critical-sized defect models was introduced. Critical-sized defects were not designed as a model for the clinical setting. In contrast, they were designed simply to be just large enough that they would not heal without intervention, but small enough to be sensitive to minor improvement. Subsequently, critical-sized defect models became the target against which essentially all preclinical materials were developed and optimized. It is predictable that over time,



TABLE 3. INTERNATIONAL STANDARDS ORGANIZATION 10993 STANDARDS FOR BIOLOGICAL EVALUATION OF MEDICAL DEVICES RELATED TO BONE TISSUE ENGINEERING

Name	Description
ISO 10993-1:2003	Evaluation and testing
ISO 10993-2:2006	Animal welfare requirements
ISO 10993-3:2003	Tests for genotoxicity, carcinogenicity, and reproductive toxicity
ISO 10993-4:2002	Selection of tests for interactions with blood
ISO 10993-5:1999	Tests for <i>in vitro</i> cytotoxicity
ISO 10993-6:2007	Tests for local effects after implantation
ISO 10993-7:1995	Ethylene oxide sterilization residuals
ISO 10993-8:	Selection of reference materials
ISO 10993-9:1999	Framework for identification and quantification of potential degradation products
ISO 10993-10:2002	Tests for irritation and delayed-type hypersensitivity
ISO 10993-11:2006	Tests for systemic toxicity
ISO 10993-12:2007	Sample preparation and reference materials (available in English only)
ISO 10993-13:1998	Identification and quantification of degradation products from polymeric medical devices
ISO 10993-14:2001	Identification and quantification of degradation products from ceramics
ISO 10993-15:2000	Identification and quantification of degradation products from metals and alloys
ISO 10993-16:1997	Toxicokinetic study design for degradation products and leachables
ISO 10993-17:2002	Establishment of allowable limits for leachable substances
ISO 10993-18:2005	Chemical characterization of materials
ISO/TS 10993-19:2006	Physicochemical, morphological, and topographical characterization of materials
ISO/TS 10993-20:2006	Principles and methods for immunotoxicology testing of medical devices

ISO, International Standards Organization.

through incremental improvement, available materials and methods have now been refined to the point where even large defects in large animals can be healed at a high rate of success. However, as discussed in the previous paragraph, when materials are then used clinically in comparable defects but in settings of systemic and local biology that were not part of the previous optimization scheme, performance will predictably fall. Several different technology strategies are now available that achieve virtually 100% success rates in large animal defect models in preclinical studies,<sup>218,231–234</sup> but demonstrate substantial failure rates and, in some cases, clinical complications that were not predicted by preclinical models.<sup>235–237</sup>

Insensitivity to incremental improvement is also a predictable outcome of systematic optimization of materials for a limited set of models, be the critical-sized defects or spine fusion models. As available materials and strategies are improved, results improve, narrowing the remaining window for detecting further benefit. This situation has now developed even in the setting of rigorous 5-cm defects in large animal models, where several treatment strategies now demonstrate near 100% success.<sup>238–240</sup> This creates an urgent need for more rigorous and more biologically relevant preclinical models. This challenge is discussed further under the section Gaps and Opportunities, below.

The final missing link between preclinical prediction of performance and true clinical performance is the fact that the true clinical use and performance of virtually all current products and bone tissue engineering strategies is not known. Actual clinical results of bone grafting procedures are reported in only a small percentage of cases. Data for some materials in some clinical settings are available from randomized trials, though this is limited almost exclusively to trials that are required by the FDA or another agency. Most often, outcome is reported only in relatively small retrospective case series of 10–100 patients in a limited field of application and is based on the experience of a small number

of surgeons at elite medical centers. However, regardless of setting, these reports are inevitably prone to at least two sources of bias, selective inquiry (choosing to study what is already suspected to be a good series) and publication bias (choosing or being able to publish only positive results), and as a result the systematic underreporting of adverse outcomes.

Currently, all but one of the FDA-approved products for bone repair have been approved by the 510-k mechanism. This mechanism of approval does not require large-scale premarketing clinical studies or systematic data collection or systematic reporting of clinical outcomes during the post-marketing period. These current conditions make it very difficult to determine the settings in which the current products are used, the way in which they are being used, or to provide an objective correlation between performance in preclinical studies and clinical performance.

This deficiency in our current knowledge of the actual utilization and objective or relative performance across the many products now marketed for bone repair and regeneration and other applications has become more apparent as both the number of competing product options and expectation for performance have increased. This recognition is catalyzing an important national discussion, legislation,<sup>241</sup> and investments in research funding to develop capabilities for a national registry of medical devices and biomedical implants. Despite these limitations and caveats, preclinical assessment of new therapy options using robust and well-defined animal models remains a central pillar in the armamentarium of tissue engineers seeking to advance clinical practice.

#### Gaps and Opportunities to Improve upon Existing Animal Models

Despite these advantages of critical-sized defect models, there are obviously some major limitations. Understanding



the effects of aging on the clinical efficacy has already been mentioned as one major gap. The second gap is the dependency of existing models on critical-sized defects, in which only defect size is used to "elevate the bar," without including other systemic and local biological factors that are known to have profound clinical relevance and effects.

The defects used in virtually all current animal models involve grafting into defects in which the biological environment is characterized by a clean, freshly cut vascular bone and a relatively untraumatized and well-vascularized soft tissue envelope. This biological environment may be found in a defect created by the excision of a low-grade malignant tumor (e.g., low-grade chondrosarcoma) in which no systemic chemotherapy or local radiation therapy will be used, but will be true in very few other settings. In contrast, the local biological environment in the vast majority of clinical defects is inevitably characterized not just by a bone defect, but also by combined deficits of local periosteum, soft tissue (muscle and fat), compromise of vascularity in local tissues, and often the effects of local changes in tissue quality and composition resulting from local disease or prior injury and scarring.

Some investigators using some models do attempt to add these local features to the model. Some examples include extending the excision, elevation, or trauma to periosteum beyond the defect by a fixed distance, and irrigating or reaming bone marrow tissue from the bone ends at the edge of the defect. The effect of these insults may improve modeling of the clinical setting in at least three ways. First, they may reduce the local concentration and prevalence of osteogenic progenitors by removing or injuring tissues in which these populations reside. Second, the procedures may simply compromise local vascularity to bone and soft tissue around the defect site, creating a more profound challenge to mass transport of oxygen and other nutrients in the site. Finally, the extra trauma may increase the amount of local necrosis, inflammation, bleeding, and subsequent scarring. Other parameters can be imposed, such as excision of local muscle or fat, cauterization, and freezing of local tissue. All of these factors are more difficult to perform in a reproducible fashion than cutting out a bone defect, but the combination of these additionally local biological factors will likely be necessary to "raise the bar" of existing defect models to both enhance the clinical relevance and specificity of animal models, and to enhance the sensitivity of these models in detecting further incremental improvements in efficacy.

## Conclusions

Bone is a complex composite organ composed of a unique mineralized matrix that functions in a highly integrated fashion with vascular, hematopoietic, and adipose tissues. As a result, the scientific questions related to bone health, pathology, and disease and regeneration demand the use of a broad range of animal models, and the continued need for innovation in new model systems to advance the field of regenerative medicine. Opportunities for advancement of animal models are identified in at least four domains: (1) the continued development of models to address new questions and relevant variables and outcome parameters (e.g., cell survival, cell homing and cell state transition events, mass transport, *in vivo* cytokine delivery kinetics, and defined genetic or signaling modification); (2) application of new methods of quantitative

analysis (e.g., imaging modalities, histology or biophysical to elucidate features of existing models that have not been generally accessible); (3) improved standardization, validation, and rigorous use of models in competitive analyses that are intended to provide predictive value with respect to relative clinical performance; and (4) the design and implementation of models that better represent the complex environment in which clinical bone regeneration procedures are often performed and most often fail (larger regions characterized by bone and tissue loss, scarring, compromised vascularity, and a functional deficiency of local stem cell and progenitor cell populations).

## Acknowledgments

The authors would like to acknowledge Lyman Jellema and the Cleveland Museum of Natural History for assistance with femur samples and associated discussion. The authors would also like to thank Richard Rozic, Amit Vasanji, and the Cleveland Clinic Musculoskeletal Imaging Core/Image Processing and Analysis Center for assistance and guidance regarding the microCT scanning of distal femurs.

## Disclosure Statement

The authors have no commercial associations or competing financial interests in connection with this article.

## References

1. Muschler, G.F., Nakamoto, C., and Griffith, L.G. Engineering principles of clinical cell based tissue engineering. *J Bone Joint Surg Am* **86-A**, 1541, 2004.
2. Muschler, G.F., and Midura, R.J. Connective tissue progenitors: practical concepts for clinical applications. *Clin Ortho* **395**, 66, 2002.
3. Muschler, G.F., Midura, R.J., and Nakamoto, C. Practical modeling concepts for connective tissue stem cell and progenitor compartment kinetics. *J Biomed Biotechnol* **2003**, 170, 2003.
4. Goodell, M.A., Brose, K., Paradis, G., Conner, A.S., and Mulligan, R.C. Isolation and functional properties of murine hematopoietic stem cells that are replicating *in vivo*. *J Exp Med* **183**, 1797, 1996.
5. Schwartz, R.E., Reyes, M., Koodie, L., Jiang, Y., Blackstad, M., Lund, T., Lenvik, T., Johnson, S., Hu, W.S., and Verfaillie, C.M. Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte like cells. *J Clin Invest* **109**, 1291, 2002.
6. Asakura, A., and Rudnicki, M.A. Side population cells from diverse adult tissues are capable of *in vitro* hematopoietic differentiation. *Exp Hematol* **30**, 1339, 2002.
7. Jiang, Y., Jahagirdar, B.N., Reinhardt, R.L., Schwartz, R.E., Keene, C.D., Ortiz Gonzalez, X.R., Reyes, M., Lenvik, T., Lund, T., Blackstad, M., Du, J., Aldrich, S., Lisberg, A., Low, W.C., Largaespada, D.A., and Verfaillie, C.M. Pluripotency of mesenchymal stem cells derived from adult marrow. *Nature* **447**, 880, 2007.
8. Langer, R., and Vacanti, J.P. Tissue engineering. *Science* **260**, 920, 1993.
9. Muschler, G.F., Nakamoto, C., and Grauer, J.N. Chapter 3: Bone healing and bone grafting. In: Vaccaro, A.R., ed. *Orthopaedic Knowledge Update 8: Home Study Syllabus*. American Academy of Orthopaedic Surgeons, Rosemont, IL, pp. 37-50, 2005.

10. Schoonen, W.G., Westerink, W.M., and Horbach, G.J. High throughput screening for analysis of *in vitro* toxicity. *EXS* **99**, 401, 2009.
11. Colas, P. High throughput screening assays to discover small molecule inhibitors of protein interactions. *Curr Drug Discov Technol* **5**, 190, 2008.
12. Mastro, A.M., and Vogler, E.A. A three dimensional osteogenic tissue model for the study of metastatic tumor cell interactions with bone. *Cancer Res* **69**, 4097, 2009.
13. Patterson, T.E., Kumagai, K., Griffith, L., and Muschler, G.F. Cellular strategies for enhancement of fracture repair. *J Bone Joint Surg Am* **90 Suppl 1**, 111, 2008.
14. Kumagai, K., Vasanthi, A., Drazba, J.A., Butler, R.S., and Muschler, G.F. Circulating cells with osteogenic potential are physiologically mobilized into the fracture healing site in the parabiotic mice model. *J Orthop Res* **26**, 165, 2008.
15. Judex, S., Gupta, S., and Rubin, C. Regulation of mechanical signals in bone. *Orthod Craniofac Res* **12**, 94, 2009.
16. American Society for Testing and Materials, [www.astm.org](http://www.astm.org).
17. International Organization for Standardization, [www.iso.org](http://www.iso.org).
18. United States Food and Drug Administration, [www.fda.gov](http://www.fda.gov).
19. European Commission, <http://ec.europa.eu>.
20. Barnes, B., Boden, S.D., Louis Ugbo, J., Tomak, P.R., Park, J.S., Park, M.S., and Minamide, A. Lower dose of rhBMP 2 achieves spine fusion when combined with an osteoconductive bulking agent in non human primates. *Spine* **30**, 1127, 2005.
21. Boden, S.D., Zdeblick, T.A., Sandhu, H.S., and Heim, S.E. The use of rhBMP 2 in interbody fusion cages. Definitive evidence of osteoinduction in humans: a preliminary report. *Spine* **25**, 376, 2000.
22. Breitbart, A.S., Grande, D.A., Mason, J.M., Barcia, M., James, T., and Grant, R.T. Gene enhanced tissue engineering: applications for bone healing using cultured periosteal cells transduced retrovirally with the BMP 7 gene. *Ann Plast Surg* **42**, 488, 1999.
23. Cowan, C.M., Aghaloo, T., Chou, Y.F., Walder, B., Zhang, X., Soo, C., Ting, K., and Wu, B. MicroCT evaluation of three dimensional mineralization in response to BMP 2 doses *in vitro* and in critical sized rat calvarial defects. *Tissue Eng* **13**, 501, 2007.
24. Dai, K.R., Xu, X.L., Tang, T.T., Zhu, Z.A., Yu, C.F., Xu, M., Zhu, L.L., Hao, Y.Q., and Lou, J.R. [BMP 2 gene modified tissue engineered bone repairing segmental tibial bone defects in goats]. *Zhonghua Yi Xue Za Zhi* **83**, 1345, 2003.
25. Dellinger, J.G., Eurell, J.A., Stewart, M., and Jamison, R.D. Bone response to 3D periodic hydroxyapatite scaffolds with and without tailored microporosity to deliver bone morphogenetic protein 2. *J Biomed Mater Res A* **76**, 366, 2006.
26. Fischer, L., Boland, G., and Tuan, R.S. Wnt signaling during BMP 2 stimulation of mesenchymal chondrogenesis. *J Cell Biochem* **84**, 816, 2002.
27. Friedlaender, G.E., Perry, C.R., Cole, J.D., Cook, S.D., Cierny, G., Muschler, G.F., Zych, G.A., Calhoun, J.H., LaForté, A.J., and Yin, S. Osteogenic protein 1 (bone morphogenetic protein 7) in the treatment of tibial nonunions. *J Bone Joint Surg Am* **83-A Suppl 1**, S151, 2001.
28. Hou, R., Chen, F., Yang, Y., Cheng, X., Gao, Z., Yang, H.O., Wu, W., and Mao, T. Comparative study between coral mesenchymal stem cells rhBMP 2 composite and auto bone graft in rabbit critical sized cranial defect model. *J Biomed Mater Res A* **80**, 85, 2007.
29. Jones, C.B., Sabatino, C.T., Badura, J.M., Sietsema, D.L., and Marotta, J.S. Improved healing efficacy in canine ulnar segmental defects with increasing recombinant human bone morphogenetic protein 2/allograft ratios. *J Orthop Trauma* **22**, 550, 2008.
30. Liao, S.S., Guan, K., Cui, F.Z., Shi, S.S., and Sun, T.S. Lumbar spinal fusion with a mineralized collagen matrix and rhBMP 2 in a rabbit model. *Spine* **28**, 1954, 2003.
31. Seeherman, H.J., Boussein, M., Kim, H., Li, R., Li, X.J., Aiolo, M., and Wozney, J.M. Recombinant human bone morphogenetic protein 2 delivered in an injectable calcium phosphate paste accelerates osteotomy site healing in a nonhuman primate model. *J Bone Joint Surg Am* **86-A**, 1961, 2004.
32. Kidd, S., Spaeth, E., Klopp, A., Andreeff, M., Hall, B., and Marini, F.C. The (in) auspicious role of mesenchymal stromal cells in cancer: be it friend or foe. *Cytotherapy* **10**, 657, 2008.
33. Mishra, P.J., Glod, J.W., and Banerjee, D. Mesenchymal stem cells: flip side of the coin. *Cancer Res* **69**, 1255, 2009.
34. Halme, D.G., and Kessler, D.A. FDA regulation of stem cell based therapies. *N Engl J Med* **355**, 1730, 2006.
35. Mooney, M.P., and Siegel, M. Animal models for bone tissue engineering of critical sized defects (CSDs), bone pathologies and orthopedic disease states. In: Hollinger, J.O., Einhorn, T.A., Doll, B.A., and Sfeir, C., eds. *Bone Tissue Engineering*. Boca Raton, London, New York, and Washington, DC: CRC Press, 2005, pp. 217-244.
36. Mooney, M.P., and Siegel, M.I. Animal models for bone tissue engineering. *Encyclopedia Biomater Biomed Eng* **1**, 1, 2005.
37. Salgado, A.J., Coutinho, O.P., and Reis, R.L. Bone tissue engineering: state of the art and future trends. *Macromol Biosci* **4**, 743, 2004.
38. van Gaalen, S.M., Dhert, W.J., van den Muysenberg, A., Oner, F.C., van Blitterswijk, C., Verbout, A.J., and de Bruijn, J.D. Bone tissue engineering for spine fusion: an experimental study on ectopic and orthotopic implants in rats. *Tissue Eng* **10**, 231, 2004.
39. Viateau, V., Logeart Avramoglou, D., Guillemain, G., and Petite, H. Animal models for bone tissue engineering purposes. In: Michael Conn, ed. *Sourcebook of Models for Biomedical Research*. Totowa, NJ: Humana Press, 2008, pp. 725-736.
40. Wang, L., Liu, Y., Kalajzic, Z., Jiang, X., and Rowe, D.W. Heterogeneity of engrafted bone lining cells after systemic and local transplantation. *Blood* **106**, 3650, 2005.
41. Kumagai, K., Vasanthi, A., Drazba, J.A., Butler, R.S., and Muschler, G.F. Circulating cells with osteogenic potential are physiologically mobilized into the fracture healing site in the parabiotic mice model. *J Orthop Res* **26**, 165, 2008.
42. Zhang, X., Xie, C., Lin, A.S., Ito, H., Awad, H., Lieberman, J.R., Rubery, P.T., Schwarz, E.M., O'Keefe, R.J., and Guldberg, R.E. Periosteal progenitor cell fate in segmental cortical bone graft transplantations: implications for functional tissue engineering. *J Bone Miner Res* **20**, 2124, 2005.
43. Stevenson, S., Li, X.Q., Davy, D.T., Klein, L., and Goldberg, V.M. Critical biological determinants of incorporation of non vascularized cortical bone grafts. Quantification of a complex process and structure. *J Bone Joint Surg Am* **79**, 1, 1997.

44. Stevenson, S. Biology of bone grafts. *Orthop Clin North Am* **30**, 543, 1999.
45. Siemionow, M.Z., Izycki, D.M., and Zielinski, M. Donor specific tolerance in fully major histocompatibility major histocompatibility complex mismatched limb allograft transplants under an anti alphabeta T cell receptor monoclonal antibody and cyclosporine A protocol. *Transplantation* **76**, 1662, 2003.
46. Malaval, L., Modrowski, D., Gupta, A.K., and Aubin, J.E. Cellular expression of bone related proteins during *in vitro* osteogenesis in rat bone marrow stromal cell cultures. *J Cell Physiol* **158**, 555, 1994.
47. Majors, A.K., Boehm, C.A., Nitto, H., Midura, R.J., and Muschler, G.F. Characterization of human bone marrow stromal cells with respect to osteoblastic differentiation. *J Orthop Res* **15**, 546, 1997.
48. Muschler, G.F., Boehm, C., and Easley, K. Aspiration to obtain osteoblast progenitor cells from human bone marrow: the influence of aspiration volume. *J Bone Joint Surg Am* **79**, 1699, 1997.
49. Villarruel, S.M., Boehm, C.A., Pennington, M., Bryan, J.A., Powell, K.A., and Muschler, G.F. The effect of oxygen tension on the *in vitro* assay of human osteoblastic connective tissue progenitor cells. *J Orthop Res* **26**, 1390, 2008.
50. Yin, D., Wang, Z., Gao, Q., Sundaresan, R., Parrish, C., Yang, Q., Krebsbach, P.H., Lichtler, A.C., Rowe, D.W., Hock, J., and Liu, P. Determination of the fate and contribution of *ex vivo* expanded human bone marrow stem and progenitor cells for bone formation by 2.3ColGFP. *Mol Ther* **17**, 1967, 2009.
51. Gerstenfeld, L.C., Cho, T.J., Kon, T., Aizawa, T., Tsay, A., Fitch, J., Barnes, G.L., Graves, D.T., and Einhorn, T.A. Impaired fracture healing in the absence of TNF alpha signaling: the role of TNF alpha in endochondral cartilage resorption. *J Bone Miner Res* **18**, 1584, 2003.
52. Einhorn, T.A., Simon, G., Devlin, V.J., Warman, J., Sidhu, S.P., and Vigorita, V.J. The osteogenic response to distant skeletal injury. *J Bone Joint Surg Am* **72**, 1374, 1990.
53. Hu, J., Li, J., Wang, D., Buckley, M.J., and Agarwal, S. Differences in mandibular distraction osteogenesis after corticotomy and osteotomy. *Int J Oral Maxillofac Surg* **31**, 185, 2002.
54. Marti, C.B., and Jakob, R.P. Accumulation of irrigation fluid in the calf as a complication during high tibial osteotomy combined with simultaneous arthroscopic anterior cruciate ligament reconstruction. *Arthroscopy* **15**, 864, 1999.
55. Yacker, M.J., and Klein, M. The effect of irrigation on osteotomy depth and bur diameter. *Int J Oral Maxillofac Implants* **11**, 634, 1996.
56. Bedi, A., and Karunakar, M.A. Physiologic effects of intramedullary reaming. *Instr Course Lect* **55**, 359, 2006.
57. Bhandari, M., Guyatt, G.H., Tornetta, P., 3rd, Swiontkowski, M.F., Hanson, B., Sprague, S., Syed, A., and Schemitsch, E.H. Current practice in the intramedullary nailing of tibial shaft fractures: an international survey. *J Trauma* **53**, 725, 2002.
58. Giannoudis, P.V., Snowden, S., Matthews, S.J., Smye, S.W., and Smith, R.M. Friction burns within the tibia during reaming. Are they affected by the use of a tourniquet? *J Bone Joint Surg Br* **84**, 492, 2002.
59. Bassey, L.O. Valgus deformity following proximal metaphyseal fractures in children: experiences in the African tropics. *J Trauma* **30**, 102, 1990.
60. Eckardt, H., Christensen, K.S., Lind, M., Hansen, E.S., Hall, D.W., and Hvid, I. Recombinant human bone morphogenetic protein 2 enhances bone healing in an experimental model of fractures at risk of non union. *Injury* **36**, 489, 2005.
61. Russell, A.J. Standardized experimental procedures in tissue engineering: cure or curse. *Tissue Eng* **11**, vii, 2005.
62. Brozmanova, E., and Skrovina, B. Serum enzyme activity in bone tumors and osteomyelitis (LDH, GOT, GPT, CPK, CHE, ALP, AP, PP, ALD). *Neoplasma* **24**, 109, 1977.
63. Kiel, D.P., Ferrari, S.L., Cupples, L.A., Karasik, D., Manen, D., Imamovic, A., Herbert, A.G., and Dupuis, J. Genetic variation at the low density lipoprotein receptor related protein 5 (LRP5) locus modulates Wnt signaling and the relationship of physical activity with bone mineral density in men. *Bone* **40**, 587, 2007.
64. Fang, Y., van Meurs, J.B., Rivadeneira, F., van Schoor, N.M., van Leeuwen, J.P., Lips, P., Pols, H.A., and Uitterlinden, A.G. Vitamin D receptor gene haplotype is associated with body height and bone size. *J Clin Endocrinol Metab* **92**, 1491, 2007.
65. O'Loughlin, P.F., Morr, S., Bogunovic, L., Kim, A.D., Park, B., and Lane, J.M. Selection and development of preclinical models in fracture healing research. *J Bone Joint Surg Am* **90 Suppl 1**, 79, 2008.
66. Hollinger, J.O., and Citron, M. Considerations for the *in vivo* testing of biomaterials. In: Hollinger, J.O., and Guelcher, S.A., eds. *An Introduction to Biomaterials*. Boca Raton, FL: CRC Press, 2006, pp. 81-104.
67. Hollinger, J.O., and Kleinschmidt, J.C. The critical size defect as an experimental model to test bone repair materials. *J Craniofac Surg* **1**, 60, 1990.
68. Pearce, A.I., Richards, R.G., Milz, S., Schneider, E., and Pearce, S.G. Animal models for implant biomaterial research in bone: a review. *Eur Cell Mater* **13**, 1, 2007.
69. Reichert, J.C., Saifzadeh, S., Wulschleger, M.E., Epari, D.R., Schutz, M.A., Duda, G.N., Schell, H., van Griensven, M., Redl, H., and Hutmacher, D.W. The challenge of establishing preclinical models for segmental bone defect research. *Biomaterials* **30**, 2149, 2009.
70. Reinwald, S., and Burr, D. Review of nonprimate, large animal models for osteoporosis research. *J Bone Miner Res* **23**, 1353, 2008.
71. Schmitz, J.P., and Hollinger, J.O. The critical size defect as an experimental model for craniomandibulofacial non unions. *Clin Orthop Relat Res* **444**, 299, 1986.
72. An, Y.a., and Friedman, R. Animal models of bone defect repair. In: Yuehuei, H.An, and Friedman, R.J., eds. *Animal Models in Orthopaedic Research*. Boca Raton, FL: CRC Press, 1998, pp. 241-260.
73. Boden, S.D., Grob, D., and Damien, C. Ne Osteo bone growth factor for posterolateral lumbar spine fusion: results from a nonhuman primate study and a prospective human clinical pilot study. *Spine* **29**, 504, 2004.
74. Ripamonti, U., Van Den Heever, B., Sampath, T.K., Tucker, M.M., Rueger, D.C., and Reddi, A.H. Complete regeneration of bone in the baboon by recombinant human osteogenic protein 1 (hOP 1, bone morphogenetic protein 7). *Growth Factors* **13**, 273, 1996.
75. Einhorn, T.A., Lane, J.M., Burstein, A.H., Kopman, C.R., and Vigorita, V.J. The healing of segmental bone defects induced by demineralized bone matrix. A radiographic and biomechanical study. *J Bone Joint Surg Am* **66**, 274, 1984.
76. Boden, S.D., Moskovitz, P.A., Morone, M.A., and Toribitake, Y. Video assisted lateral intertransverse process

- arthrodesis. Validation of a new minimally invasive lumbar spinal fusion technique in the rabbit and nonhuman primate (rhesus) models. *Spine* **21**, 2689, 1996.
77. Cheng, J.C., Guo, X., Law, L.P., Lee, K.M., Chow, D.H., and Rosier, R. How does recombinant human bone morphogenetic protein 4 enhance posterior spinal fusion? *Spine (Phila Pa 1976)* **27**, 467, 2002.
  78. France, J.C., Norman, T.L., Santrock, R.D., McGrath, B., and Simon, B.J. The efficacy of direct current stimulation for lumbar intertransverse process fusions in an animal model. *Spine (Phila Pa 1976)* **26**, 1002, 2001.
  79. Guo, X., Lee, K.M., Law, L.P., Chow, H.K., Rosier, R., and Cheng, C.Y. Recombinant human bone morphogenetic protein 4 (rhBMP 4) enhanced posterior spinal fusion without decortication. *J Orthop Res* **20**, 740, 2002.
  80. Kraiattanapong, C., Boden, S.D., Louis Ugbo, J., Attallah, E., Barnes, B., and Hutton, W.C. Comparison of Healos/ bone marrow to INFUSE(rhBMP 2/ACS) with a collagen ceramic sponge bulking agent as graft substitutes for lumbar spine fusion. *Spine (Phila Pa 1976)* **30**, 1001, 2005.
  81. Minamide, A., Kawakami, M., Hashizume, H., Sakata, R., and Tamaki, T. Evaluation of carriers of bone morphogenetic protein for spinal fusion. *Spine (Phila Pa 1976)* **26**, 933, 2001.
  82. Silcox, D.H., 3rd, Daftari, T., Boden, S.D., Schimandle, J.H., Hutton, W.C., and Whitesides, T.E., Jr. The effect of nicotine on spinal fusion. *Spine (Phila Pa 1976)* **20**, 1549, 1995.
  83. Yee, A.J., Bae, H.W., Friess, D., Roth, S.M., Whyne, C., Robbin, M., Johnstone, B., and Yoo, J.U. The use of simvastatin in rabbit posterolateral lumbar intertransverse process spine fusion. *Spine J* **6**, 391, 2006.
  84. Korres, D.S., Babis, G.C., Paraskevakou, H., Stamos, K., Tsarouchas, J., and Lykometros, V. Spontaneous interbody fusion after controlled injuries to the spine: an experimental study in rabbits. *J Spinal Disord* **13**, 31, 2000.
  85. Feighan, J.E., Stevenson, S., and Emery, S.E. Biologic and biomechanic evaluation of posterior lumbar fusion in the rabbit. The effect of fixation rigidity. *Spine (Phila Pa 1976)* **20**, 1561, 1995.
  86. Kahanovitz, N., Arnoczky, S.P., Hulse, D., and Shires, P.K. The effect of postoperative electromagnetic pulsing on canine posterior spinal fusions. *Spine (Phila Pa 1976)* **9**, 273, 1984.
  87. Kioschos, H.C., Asher, M.A., Lark, R.G., and Harner, E.J. Overpowering the crankshaft mechanism. The effect of posterior spinal fusion with and without stiff transpedicular fixation on anterior spinal column growth in immature canines. *Spine (Phila Pa 1976)* **21**, 1168, 1996.
  88. Takemoto, M., Fujibayashi, S., Neo, M., So, K., Akiyama, N., Matsushita, T., Kokubo, T., and Nakamura, T. A porous bioactive titanium implant for spinal interbody fusion: an experimental study using a canine model. *J Neurosurg Spine* **7**, 435, 2007.
  89. Muschler, G.F., Huber, B., Ullman, T., Barth, R., Easley, K., Otis, J.O., and Lane, J.M. Evaluation of bone grafting materials in a new canine segmental spinal fusion model. *J Orthop Res* **11**, 514, 1993.
  90. Muschler, G.F., Hyodo, A., Manning, T., Kambic, H., and Easley, K. Evaluation of human bone morphogenetic protein 2 in a canine spinal fusion model. *Clin Orthop Relat Res* **308**, 229, 1994.
  91. Muschler, G.F., Matsukura, Y., Nitto, H., Boehm, C.A., Valdevit, A.D., Kambic, H.E., Davros, W.J., Easley, K.A., and Powell, K.A. Selective retention of bone marrow derived cells to enhance spinal fusion. *Clin Orthop Relat Res* **432**, 242, 2005.
  92. Muschler, G.F., Negami, S., Hyodo, A., Gaisser, D., Easley, K., and Kambic, H. Evaluation of collagen ceramic composite graft materials in a spinal fusion model. *Clin Orthop Relat Res* **328**, 250, 1996.
  93. Johnston, C.E., 2nd, Ashman, R.B., Baird, A.M., and Allard, R.N. Effect of spinal construct stiffness on early fusion mass incorporation. Experimental study. *Spine (Phila Pa 1976)* **15**, 908, 1990.
  94. Krijnen, M.R., Mensch, D., van Dieen, J.H., Wuisman, P.I., and Smit, T.H. Primary spinal segment stability with a stand alone cage: *in vitro* evaluation of a successful goat model. *Acta Orthop* **77**, 454, 2006.
  95. Oner, F.C., Verlaan, J.J., Verbout, A.J., and Dhert, W.J. Cement augmentation techniques in traumatic thoracolumbar spine fractures. *Spine (Phila Pa 1976)* **31**, S89, 2006.
  96. Vaccaro, A.R., and Madigan, L. Spinal applications of bioabsorbable implants. *Orthopedics* **25**, s1115, 2002.
  97. Wilson, C.E., Kruijt, M.C., de Bruijn, J.D., van Blitterswijk, C.A., Oner, F.C., Verbout, A.J., and Dhert, W.J. A new *in vivo* screening model for posterior spinal bone formation: comparison of ten calcium phosphate ceramic material treatments. *Biomaterials* **27**, 302, 2006.
  98. Blatter, T.R., Delling, G., Dalal, P.S., Toth, C.A., Balling, H., and Weckbach, A. Successful transpedicular lumbar interbody fusion by means of a composite of osteogenic protein 1 (rhBMP 7) and hydroxyapatite carrier: a comparison with autograft and hydroxyapatite in the sheep spine. *Spine (Phila Pa 1976)* **27**, 2697, 2002.
  99. Blatter, T.R., Delling, G., and Weckbach, A. Evaluation of an injectable calcium phosphate cement as an autograft substitute for transpedicular lumbar interbody fusion: a controlled, prospective study in the sheep model. *Eur Spine J* **12**, 216, 2003.
  100. Cunningham, B.W., Atkinson, B.L., Hu, N., Kikkawa, J., Jenis, L., Bryant, J., Zamora, P.O., and McAfee, P.C. Ceramic granules enhanced with B2A peptide for lumbar interbody spine fusion: an experimental study using an instrumented model in sheep. *J Neurosurg Spine* **10**, 300, 2009.
  101. Foster, M.R., Allen, M.J., Schoonmaker, J.E., Yuan, H.A., Kanazawa, A., Park, S.A., and Liu, B. Characterization of a developing lumbar arthrodesis in a sheep model with quantitative instability. *Spine J* **2**, 244, 2002.
  102. Lee, M.Y., Chang, G.L., Chang, J.H., Hung, Y.C., Chang, C.H., and Lee, E.J. Biomechanical evaluation of cervical spine fixation after healing in a destabilized cervical spine model in sheep: a comparison of the anterior plating and posterior wiring techniques. *J Trauma* **60**, 1307, 2006.
  103. Wheeler, D.L., Jenis, L.G., Kovach, M.E., Marini, J., and Turner, A.S. Efficacy of silicated calcium phosphate graft in posterolateral lumbar fusion in sheep. *Spine J* **7**, 308, 2007.
  104. Hasegawa, K., Ikeda, M., Washio, T., and Hara, T. An experimental study of porcine lumbar segmental stiffness by the distraction compression principle using a threaded interbody cage. *J Spinal Disord* **13**, 247, 2000.
  105. McLain, R.F., Yerby, S.A., and Moseley, T.A. Comparative morphometry of L4 vertebrae: comparison of large animal models for the human lumbar spine. *Spine (Phila Pa 1976)* **27**, E200, 2002.
  106. Nasca, R.J., Lemons, J.E., and Montgomery, R. Evaluation of cryopreserved bone and synthetic biomaterials in promoting spinal fusion. *Spine (Phila Pa 1976)* **16**, S330, 1991.

107. Olsson, T.H., Selvik, G., and Willner, S. Kinematic analysis of posterior spinal fusions in pigs. *Acta Radiol Diagn (Stockh)* **17**, 369, 1976.
108. Sheyn, D., Pelled, G., Zilberman, Y., Talasazan, F., Frank, J.M., Gazit, D., and Gazit, Z. Nonvirally engineered porcine adipose tissue derived stem cells: use in posterior spinal fusion. *Stem Cells* **26**, 1056, 2008.
109. Xue, Q., Li, H., Zou, X., Bunger, M., Egund, N., Lind, M., Christensen, F.B., and Bunger, C. The influence of alendronate treatment and bone graft volume on posterior lateral spine fusion in a porcine model. *Spine (Phila Pa 1976)* **30**, 1116, 2005.
110. Zhang, H., Sucato, D.J., and Welch, R.D. Recombinant human bone morphogenetic protein 2 enhanced anterior spine fusion without bone encroachment into the spinal canal: a histomorphometric study in a thoracoscopically instrumented porcine model. *Spine (Phila Pa 1976)* **30**, 512, 2005.
111. Cain, C.C., and Fraser, R.D. Bony and vascular anatomy of the normal cervical spine in the sheep. *Spine (Phila Pa 1976)* **20**, 759, 1995.
112. Goh, J.C., Wong, H.K., Thambyah, A., and Yu, C.S. Influence of PLIF cage size on lumbar spine stability. *Spine (Phila Pa 1976)* **25**, 35, 2000.
113. Kim, K.W., Ha, K.Y., Moon, M.S., Kim, Y.S., Kwon, S.Y., and Woo, Y.K. Volumetric change of the graft bone after intertransverse fusion. *Spine (Phila Pa 1976)* **24**, 428, 1999.
114. Wilke, H.J., Kettler, A., Wenger, K.H., and Claes, L.E. Anatomy of the sheep spine and its comparison to the human spine. *Anat Rec* **247**, 542, 1997.
115. Zdeblick, T.A., Cooke, M.E., Wilson, D., Kunz, D.N., and McCabe, R. Anterior cervical discectomy, fusion, and plating. A comparative animal study. *Spine (Phila Pa 1976)* **18**, 1974, 1993.
116. Boden, S.D., Martin, G.J., Jr., Horton, W.C., Truss, T.L., and Sandhu, H.S. Laparoscopic anterior spinal arthrodesis with rhBMP 2 in a titanium interbody threaded cage. *J Spinal Disord* **11**, 95, 1998.
117. Burkus, J.K., Sandhu, H.S., Gornet, M.F., and Longley, M.C. Use of rhBMP 2 in combination with structural cortical allografts: clinical and radiographic outcomes in anterior lumbar spinal surgery. *J Bone Joint Surg Am* **87**, 1205, 2005.
118. Cook, S.D., Patron, L.P., Christakis, P.M., Bailey, K.J., Banta, C., and Glazer, P.A. Direct current stimulation of titanium interbody fusion devices in primates. *Spine J* **4**, 300, 2004.
119. Hecht, B.P., Fischgrund, J.S., Herkowitz, H.N., Penman, L., Toth, J.M., and Shirkhoda, A. The use of recombinant human bone morphogenetic protein 2 (rhBMP 2) to promote spinal fusion in a nonhuman primate anterior interbody fusion model. *Spine (Phila Pa 1976)* **24**, 629, 1999.
120. Suh, D.Y., Boden, S.D., Louis Ugbo, J., Mayr, M., Murakami, H., Kim, H.S., Minamide, A., and Hutton, W.C. Delivery of recombinant human bone morphogenetic protein 2 using a compression resistant matrix in posterolateral spine fusion in the rabbit and in the non human primate. *Spine (Phila Pa 1976)* **27**, 353, 2002.
121. Barnes, B., Boden, S.D., Louis Ugbo, J., Tomak, P.R., Park, J.S., Park, M.S., and Minamide, A. Lower dose of rhBMP 2 achieves spine fusion when combined with an osteoconductive bulking agent in non human primates. *Spine (Phila Pa 1976)* **30**, 1127, 2005.
122. Martin, R.B., Chapman, M.W., Sharkey, N.A., Zissimos, S.L., Bay, B., and Shors, E.C. Bone ingrowth and mechanical properties of coralline hydroxyapatite 1 yr after implantation. *Biomaterials* **14**, 341, 1993.
123. Umoh, J.U., Sampaio, A.V., Welch, I., Pitelka, V., Goldberg, H.A., Underhill, T.M., and Holdsworth, D.W. *In vivo* micro CT analysis of bone remodeling in a rat calvarial defect model. *Phys Med Biol* **54**, 2147, 2009.
124. Sawyer, A.A., Song, S.J., Susanto, E., Chuan, P., Lam, C.X., Woodruff, M.A., Hutmacher, D.W., and Cool, S.M. The stimulation of healing within a rat calvarial defect by mPCL TCP/collagen scaffolds loaded with rhBMP 2. *Bio materials* **30**, 2479, 2009.
125. Lavandier, B., Gleizal, A., and Bera, J.C. Experimental assessment of calvarial bone defect re ossification stimulation using low intensity pulsed ultrasound. *Ultrasound Med Biol* **35**, 585, 2009.
126. Findikcioglu, K., Findikcioglu, F., Yavuzer, R., Elmas, C., and Atabay, K. Effect of platelet rich plasma and fibrin glue on healing of critical size calvarial bone defects. *J Craniofac Surg* **20**, 34, 2009.
127. Bornstein, M.M., Heynen, G., Bosshardt, D.D., and Buser, D. Effect of two bioabsorbable barrier membranes on bone regeneration of standardized defects in calvarial bone: a comparative histomorphometric study in pigs. *J Periodontol* **80**, 1289, 2009.
128. Bohnenblust, M.E., Steigelman, M.B., Wang, Q., Walker, J.A., and Wang, H.T. An experimental design to study adipocyte stem cells for reconstruction of calvarial defects. *J Craniofac Surg* **20**, 340, 2009.
129. Yu, D., Li, Q., Mu, X., Chang, T., and Xiong, Z. Bone regeneration of critical calvarial defect in goat model by PLGA/TCP/rhBMP 2 scaffolds prepared by low temperature rapid prototyping technology. *Int J Oral Maxillofac Surg* **37**, 929, 2008.
130. Yeom, H., Blanchard, S., Kim, S., Zunt, S., and Chu, T.M. Correlation between micro computed tomography and histomorphometry for assessment of new bone formation in a calvarial experimental model. *J Craniofac Surg* **19**, 446, 2008.
131. Por, Y.C., Barcelo, C.R., Salyer, K.E., Genecov, D.G., Troxel, K., Gendler, E., Elsalanty, M.E., and Opperman, L.A. Bone generation in the reconstruction of a critical size calvarial defect in an experimental model. *J Craniofac Surg* **19**, 383, 2008.
132. Gupta, D.M., Kwan, M.D., Slater, B.J., Wan, D.C., and Longaker, M.T. Applications of an athymic nude mouse model of nonhealing critical sized calvarial defects. *J Craniofac Surg* **19**, 192, 2008.
133. Pripatnanont, P., Nuntanaranont, T., Vongvatcharanon, S., and Limlertmongkol, S. Osteoconductive effects of 3 heat treated hydroxyapatites in rabbit calvarial defects. *J Oral Maxillofac Surg* **65**, 2418, 2007.
134. Moxham, J.P. Oncostatin M enhances osteoinduction in a rabbit critical calvarial defect model. *Laryngoscope* **117**, 1790, 2007.
135. Jan, A.M., Sandor, G.K., Iera, D., Mhawi, A., Peel, S., Evans, A.W., and Clokie, C.M. Hyperbaric oxygen results in an increase in rabbit calvarial critical sized defects. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* **101**, 144, 2006.
136. Develioglu, H., Saraydin, S.U., Bolayir, G., and Dupoirieux, L. Assessment of the effect of a biphasic ceramic on bone response in a rat calvarial defect model. *J Biomed Mater Res A* **77**, 627, 2006.
137. Acarturk, T.O., and Hollinger, J.O. Commercially available demineralized bone matrix compositions to regenerate

- calvarial critical sized bone defects. *Plast Reconstr Surg* **118**, 862, 2006.
138. Kanou, M., Ueno, T., Kagawa, T., Fujii, T., Sakata, Y., Ishida, N., Fukunaga, J., and Sugahara, T. Osteogenic potential of primed periosteum graft in the rat calvarial model. *Ann Plast Surg* **54**, 71, 2005.
  139. Jung, R.E., Schmoekel, H.G., Zwahlen, R., Kokovic, V., Hammerle, C.H., and Weber, F.E. Platelet rich plasma and fibrin as delivery systems for recombinant human bone morphogenetic protein 2. *Clin Oral Implants Res* **16**, 676, 2005.
  140. Pang, E.K., Im, S.U., Kim, C.S., Choi, S.H., Chai, J.K., Kim, C.K., Han, S.B., and Cho, K.S. Effect of recombinant human bone morphogenetic protein 4 dose on bone formation in a rat calvarial defect model. *J Periodontol* **75**, 1364, 2004.
  141. Francis, P.O., McPherson, J.C., 3rd, Cuenin, M.F., Hokett, S.D., Peacock, M.E., Billman, M.A., and Sharawy, M. Evaluation of a novel alloplast for osseous regeneration in the rat calvarial model. *J Periodontol* **74**, 1023, 2003.
  142. Zellin, G., Hakanson, R., and Linde, A. Gastrectomy has no effect on bone regeneration in rats despite a decrease in bone mass. *Scand J Gastroenterol* **37**, 1149, 2002.
  143. Mardas, N., Kostopoulos, L., and Karring, T. Bone and suture regeneration in calvarial defects by e PTFE membranes and demineralized bone matrix and the impact on calvarial growth: an experimental study in the rat. *J Craniofac Surg* **13**, 453, 2002.
  144. Meikle, M.C., Papaioannou, S., Ratledge, T.J., Speight, P.M., Watt Smith, S.R., Hill, P.A., and Reynolds, J.J. Effect of poly DL lactide co glycolide implants and xenogeneic bone matrix derived growth factors on calvarial bone repair in the rabbit. *Biomaterials* **15**, 513, 1994.
  145. Schmitz, J.P., Schwartz, Z., Hollinger, J.O., and Boyan, B.D. Characterization of rat calvarial nonunion defects. *Acta Anat (Basel)* **138**, 185, 1990.
  146. Allegrini, S., Jr., Yoshimoto, M., Salles, M.B., and Konig, B., Jr. The effects of bovine BMP associated to HA in maxillary sinus lifting in rabbits. *Ann Anat* **185**, 343, 2003.
  147. Asai, S., Shimizu, Y., and Ooya, K. Maxillary sinus augmentation model in rabbits: effect of occluded nasal ostium on new bone formation. *Clin Oral Implants Res* **13**, 405, 2002.
  148. Butterfield, K.J., Bennett, J., Gronowicz, G., and Adams, D. Effect of platelet rich plasma with autogenous bone graft for maxillary sinus augmentation in a rabbit model. *J Oral Maxillofac Surg* **63**, 370, 2005.
  149. Grageda, E., Lozada, J.L., Boyne, P.J., Caplanis, N., and McMillan, P.J. Bone formation in the maxillary sinus by using platelet rich plasma: an experimental study in sheep. *J Oral Implantol* **31**, 2, 2005.
  150. Gruber, R.M., Ludwig, A., Merten, H.A., Pippig, S., Kramer, F.J., and Schliephake, H. Sinus floor augmentation with recombinant human growth and differentiation factor 5 (rhGDF 5): a pilot study in the Goettingen miniature pig comparing autogenous bone and rhGDF 5. *Clin Oral Implants Res* **20**, 175, 2009.
  151. Haas, R., Haidvogel, D., Donath, K., and Watzek, G. Freeze dried homogeneous and heterogeneous bone for sinus augmentation in sheep. Part I: histological findings. *Clin Oral Implants Res* **13**, 396, 2002.
  152. Lee, H.J., Choi, B.H., Jung, J.H., Zhu, S.J., Lee, S.H., Huh, J.Y., You, T.M., and Li, J. Maxillary sinus floor augmentation using autogenous bone grafts and platelet enriched fibrin glue with simultaneous implant placement. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* **103**, 329, 2007.
  153. Roldan, J.C., Kneuppel, H., Schmidt, C., Jepsen, S., Zimmermann, C., and Terheyden, H. Single stage sinus augmentation with cancellous iliac bone and anorganic bovine bone in the presence of platelet rich plasma in the miniature pig. *Clin Oral Implants Res* **19**, 373, 2008.
  154. Schlegel, K.A., Zimmermann, R., Thorwarth, M., Neukam, F.W., Klongnoi, B., Nkenke, E., and Felszeghy, E. Sinus floor elevation using autogenous bone or bone substitute combined with platelet rich plasma. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* **104**, e15, 2007.
  155. Wada, K., Niimi, A., Watanabe, K., Sawai, T., and Ueda, M. Maxillary sinus floor augmentation in rabbits: a comparative histologic histomorphometric study between rhBMP 2 and autogenous bone. *Int J Periodontics Restorative Dent* **21**, 252, 2001.
  156. Barboza, E.P., Duarte, M.E., Geolas, L., Sorensen, R.G., Riedel, G.E., and Wikesjo, U.M. Ridge augmentation following implantation of recombinant human bone morphogenetic protein 2 in the dog. *J Periodontol* **71**, 488, 2000.
  157. Gaggl, A., Schultes, G., Regauer, S., and Karcher, H. Healing process after alveolar ridge distraction in sheep. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* **90**, 420, 2000.
  158. von Arx, T., Cochran, D.L., Hermann, J.S., Schenk, R.K., and Buser, D. Lateral ridge augmentation using different bone fillers and barrier membrane application. A histologic and histomorphometric pilot study in the canine mandible. *Clin Oral Implants Res* **12**, 260, 2001.
  159. Barboza, E.P., de Souza, R.O., Caula, A.L., Neto, L.G., Caula Fde, O., and Duarte, M.E. Bone regeneration of localized chronic alveolar defects utilizing cell binding peptide associated with anorganic bovine derived bone mineral: a clinical and histological study. *J Periodontol* **73**, 1153, 2002.
  160. Donos, N., Kostopoulos, L., and Karring, T. Alveolar ridge augmentation using a resorbable copolymer membrane and autogenous bone grafts. An experimental study in the rat. *Clin Oral Implants Res* **13**, 203, 2002.
  161. Donos, N., Kostopoulos, L., and Karring, T. Augmentation of the rat jaw with autogeneic cortico cancellous bone grafts and guided tissue regeneration. *Clin Oral Implants Res* **13**, 192, 2002.
  162. Donos, N., Kostopoulos, L., and Karring, T. Alveolar ridge augmentation by combining autogenous mandibular bone grafts and non resorbable membranes. *Clin Oral Implants Res* **13**, 185, 2002.
  163. Cranin, A.N., Demirdjan, E., and DiGregorio, R. A comparison of allogeneic and autogenous iliac monocortical grafts to augment the deficient alveolar ridge in a canine model. I. Clinical study. *J Oral Implantol* **29**, 124, 2003.
  164. De Kok, I.J., Peter, S.J., Archambault, M., van den Bos, C., Kadiyala, S., Aukhil, I., and Cooper, L.F. Investigation of allogeneic mesenchymal stem cell based alveolar bone formation: preliminary findings. *Clin Oral Implants Res* **14**, 481, 2003.
  165. Jovanovic, S.A., Hunt, D.R., Bernard, G.W., Spiekermann, H., Nishimura, R., Wozney, J.M., and Wikesjo, U.M. Long term functional loading of dental implants in rhBMP 2 induced bone. A histologic study in the canine ridge augmentation model. *Clin Oral Implants Res* **14**, 793, 2003.
  166. Olsen, M.L., Aaboe, M., Hjorting Hansen, E., and Hansen, A.K. Problems related to an intraoral approach for ex

- peridental surgery on minipigs. *Clin Oral Implants Res* **15**, 333, 2004.
167. Sanchez, A.R., Sheridan, P.J., Eckert, S.E., and Weaver, A.L. Influence of platelet rich plasma added to xenogeneic bone grafts in periimplant defects: a vital fluorescence study in dogs. *Clin Implant Dent Relat Res* **7**, 61, 2005.
  168. Simion, M., Rocchietta, I., Kim, D., Nevins, M., and Fiorellini, J. Vertical ridge augmentation by means of deproteinized bovine bone block and recombinant human platelet derived growth factor BB: a histologic study in a dog model. *Int J Periodontics Restorative Dent* **26**, 415, 2006.
  169. Schwarz, F., Herten, M., Sager, M., Bieling, K., Sculean, A., and Becker, J. Comparison of naturally occurring and ligature induced peri implantitis bone defects in humans and dogs. *Clin Oral Implants Res* **18**, 161, 2007.
  170. Rothamel, D., Schwarz, F., Herten, M., Ferrari, D., Mischkowski, R.A., Sager, M., and Becker, J. Vertical ridge augmentation using xenogenous bone blocks: a histomorphometric study in dogs. *Int J Oral Maxillofac Implants* **24**, 243, 2009.
  171. Wikesjo, U.M., Qahash, M., Huang, Y.H., Xiropaidis, A., Polimeni, G., and Susin, C. Bone morphogenetic proteins for periodontal and alveolar indications; biological observations clinical implications. *Orthod Craniofac Res* **12**, 263, 2009.
  172. Sherris, D.A., Murakami, C.S., Larrabee, W.F., Jr., and Bruce, A.G. Mandibular reconstruction with transforming growth factor beta1. *Laryngoscope* **108**, 368, 1998.
  173. Fritz, M.E., Jeffcoat, M.K., Reddy, M., Koth, D., Braswell, L.D., Malmquist, J., and Lemons, J. Guided bone regeneration of large mandibular defects in a primate model. *J Periodontol* **71**, 1484, 2000.
  174. Saadeh, P.B., Khosla, R.K., Mehrara, B.J., Steinbrech, D.S., McCormick, S.A., DeVore, D.P., and Longaker, M.T. Repair of a critical size defect in the rat mandible using allogenic type I collagen. *J Craniofac Surg* **12**, 573, 2001.
  175. Shigeno, K., Nakamura, T., Inoue, M., Ueda, H., Kobayashi, E., Nakahara, T., Lynn, A.K., Toba, T., Yoshitani, M., Fukuda, S., Kawanami, R., and Shimizu, Y. Regenerative repair of the mandible using a collagen sponge containing TGF beta1. *Int J Artif Organs* **25**, 1095, 2002.
  176. Schortinghuis, J., Ruben, J.L., Meijer, H.J., Bronckers, A.L., Raghoobar, G.M., and Stegenga, B. Microradiography to evaluate bone growth into a rat mandibular defect. *Arch Oral Biol* **48**, 155, 2003.
  177. Carstens, M.H., Chin, M., and Li, X.J. *In situ* osteogenesis: regeneration of 10 cm mandibular defect in porcine model using recombinant human bone morphogenetic protein 2 (rhBMP 2) and Helistat absorbable collagen sponge. *J Craniofac Surg* **16**, 1033, 2005.
  178. Ekholm, M., Hietanen, J., Tulamo, R.M., Muhonen, J., Lindqvist, C., Kellomaki, M., and Suuronen, R. The copolymer of epsilon caprolactone lactide and tricalcium phosphate does not enhance bone growth in mandibular defect of sheep. *J Mater Sci Mater Med* **17**, 139, 2006.
  179. Okafuji, N., Shimizu, T., Watanabe, T., Kimura, A., Kurihara, S., Arai, Y., Furusawa, K., Hasegawa, H., and Kawakami, T. Three dimensional observation of reconstruction course of rabbit experimental mandibular defect with rhBMP 2 and atelocollagen gel. *Eur J Med Res* **11**, 351, 2006.
  180. Wu, W., Chen, X., Mao, T., Chen, F., and Feng, X. Bone marrow derived osteoblasts seeded into porous beta tricalcium phosphate to repair segmental defect in canine's mandibula. *Ulus Travma Acil Cerrahi Derg* **12**, 268, 2006.
  181. Sacco, A.G., and Chepeha, D.B. Current status of transport disc distraction osteogenesis for mandibular reconstruction. *Lancet Oncol* **8**, 323, 2007.
  182. Zheng, Y., Liu, Y., Zhang, C.M., Zhang, H.Y., Li, W.H., Shi, S., Le, A.D., and Wang, S.L. Stem cells from deciduous tooth repair mandibular defect in swine. *J Dent Res* **88**, 249, 2009.
  183. Siu, W.S., Qin, L., Cheung, W.H., and Leung, K.S. A study of trabecular bones in ovariectomized goats with micro computed tomography and peripheral quantitative computed tomography. *Bone* **35**, 21, 2004.
  184. Cerroni, A.M., Tomlinson, G.A., Turnquist, J.E., and Grynpas, M.D. Bone mineral density, osteopenia, and osteoporosis in the rhesus macaques of Cayo Santiago. *Am J Phys Anthropol* **113**, 389, 2000.
  185. Achari, Y., Reno, C.R., Tsao, H., Morck, D.W., and Hart, D.A. Influence of timing (pre puberty or skeletal maturity) of ovariectomy on mRNA levels in corneal tissues of female rabbits. *Mol Vis* **14**, 443, 2008.
  186. Canine Skeletal Development and Soundness. [www.eukanuba.scienceonline.com/download/slibrary/Canine%20Skeletal 1998TNAVC.pdf](http://www.eukanuba.scienceonline.com/download/slibrary/Canine%20Skeletal%201998TNAVC.pdf).
  187. Rieppo, J., Hyttinen, M.M., Halmesmaki, E., Ruotsalainen, H., Vasara, A., Kiviranta, I., Jurvelin, J.S., and Helminen, H.J. Changes in spatial collagen content and collagen network architecture in porcine articular cartilage during growth and maturation. *Osteoarthritis Cartilage* **17**, 448, 2009.
  188. Akens, M.K., and Hurtig, M.B. Influence of species and anatomical location on chondrocyte expansion. *BMC Musculoskelet Disord* **6**, 23, 2005.
  189. Animal Diversity Web. <http://animaldiversity.ummz.umich.edu/>.
  190. Kabata, T., Kubo, T., Matsumoto, T., Hirata, T., Fujioka, M., Takahashi, K.A., Yagishita, S., Kobayashi, M., and Tomita, K. Onset of steroid induced osteonecrosis in rabbits and its relationship to hyperlipaemia and increased free fatty acids. *Rheumatology (Oxford)* **44**, 1233, 2005.
  191. Miyanishi, K., Yamamoto, T., Irida, T., Yamashita, A., Jingushi, S., Noguchi, Y., and Iwamoto, Y. Bone marrow fat cell enlargement and a rise in intraosseous pressure in steroid treated rabbits with osteonecrosis. *Bone* **30**, 185, 2002.
  192. Yamamoto, T., Irida, T., Sugioka, Y., and Sueishi, K. Effects of pulse methylprednisolone on bone and marrow tissues: corticosteroid induced osteonecrosis in rabbits. *Arthritis Rheum* **40**, 2055, 1997.
  193. Bensusan, J.S., Davy, D.T., Goldberg, V.M., Shaffer, J.W., Stevenson, S., Klein, L., and Field, G. The effects of vascularity and cyclosporin A on the mechanical properties of canine fibular autografts. *J Biomech* **25**, 415, 1992.
  194. Stevenson, S. The immune response to osteochondral allografts in dogs. *J Bone Joint Surg Am* **69**, 573, 1987.
  195. Stevenson, S., Hohn, R.B., and Templeton, J.W. Effects of tissue antigen matching on the healing of fresh cancellous bone allografts in dogs. *Am J Vet Res* **44**, 201, 1983.
  196. Stevenson, S., Li, X.Q., and Martin, B. The fate of cancellous and cortical bone after transplantation of fresh and frozen tissue antigen matched and mismatched osteochondral allografts in dogs. *J Bone Joint Surg Am* **73**, 1143, 1991.
  197. Stevenson, S., Shaffer, J.W., and Goldberg, V.M. The humoral response to vascular and nonvascular allografts of bone. *Clin Orthop Relat Res* **326**, 86, 1996.
  198. Vasseur, P.B., Rodrigo, J.J., Stevenson, S., Clark, G., and Sharkey, N. Replacement of the anterior cruciate ligament



- with a bone ligament bone anterior cruciate ligament allo graft in dogs. *Clin Orthop Relat Res* **219**, 268, 1987.
199. Welter, J.F., Shaffer, J.W., Stevenson, S., Davy, D.T., Field, G.A., Klein, L., Li, X.Q., Zika, J.M., and Goldberg, V.M. Cyclosporin A and tissue antigen matching in bone trans plantation. Fibular allografts studied in the dog. *Acta Or thop Scand* **61**, 517, 1990.
  200. Bos, G.D., Goldberg, V.M., Powell, A.E., Heiple, K.G., and Zika, J.M. The effect of histocompatibility matching on ca nine frozen bone allografts. *J Bone Joint Surg Am* **65**, 89, 1983.
  201. Goldberg, M., Luk, S.C., Greyson, N.D., and Greenaway, A. Canine lung allotransplantation: donor pretreatment. *Ann Thorac Surg* **24**, 462, 1977.
  202. Goldberg, V.M., Bos, G.D., Heiple, K.G., Zika, J.M., and Powell, A.E. Improved acceptance of frozen bone allografts in genetically mismatched dogs by immunosuppression. *J Bone Joint Surg Am* **66**, 937, 1984.
  203. Deeg, H.J., Storb, R., Weiden, P.L., Shulman, H.M., Gra ham, T.C., Torok Storb, B.J., and Thomas, E.D. Abrogation of resistance to and enhancement of DLA nonidentical un related marrow grafts in lethally irradiated dogs by tho racic duct lymphocytes. *Blood* **53**, 552, 1979.
  204. Deeg, H.J., Storb, R., Weiden, P.L., Torok Storb, B.J., Gra ham, T.C., and Thomas, E.D. Resistance to marrow grafts in dogs mediated by antigens close to but not identical with DLA A, B, and C and overcome by infusion of thoracic duct lymphocytes. *Transplant Proc* **11**, 1495, 1979.
  205. Storb, R., Weiden, P.L., Deeg, H.J., Torok Storb, B., Atkin son, K., Graham, T.C., and Thomas, E.D. Marrow graft studies in dogs. *Haematol Blood Transfus* **25**, 43, 1980.
  206. Zaucha, J.M., Zellmer, E., Georges, G., Little, M.T., Storb, R., Storer, B., and Torok Storb, B. G CSF mobilized periph eral blood mononuclear cells added to marrow facilitates engraftment in nonmyeloablated canine recipients: CD3 cells are required. *Biol Blood Marrow Transplant* **7**, 613, 2001.
  207. Egermann, M., Goldhahn, J., and Schneider, E. Animal models for fracture treatment in osteoporosis. *Osteoporos Int* **16 Suppl 2**, S129, 2005.
  208. Kloss, F.R., and Gassner, R. Bone and aging: effects on the maxillofacial skeleton. *Exp Gerontol* **41**, 123, 2006.
  209. Muschler, G.F., and Lane, J.M. Spine fusion: principles of bone fusion. In: Herkowitz, H.N., Garfin, S.R., Balderston, R.A., Eismont, F.J., Bell, G.R., and Wiesel, S.W., eds. *The Spine*. Philadelphia: WB Saunders, 1999, pp. 1573 1589.
  210. ASTM Standard F2721, 2008. Standard Guide for Pre clinical *In Vivo* Evaluation in Critical Size Segmental Bone Defects. West Conshohocken, PA: ASTM International, 2003, astm.org.
  211. Aalami, O.O., Nacamuli, R.P., Lenton, K.A., Cowan, C.M., Fang, T.D., Fong, K.D., Shi, Y.Y., Song, H.M., Sahar, D.E., and Longaker, M.T. Applications of a mouse model of calvarial healing: differences in regenerative abilities of ju veniles and adults. *Plast Reconstr Surg* **114**, 713, 2004.
  212. Wang, Y.H., Allardyce, R.A., Rogers, G.R., Gillespie, W.J., and Doyle, J.S. Polymorphonuclear leukocyte mediated bone degradation and influence of blood mononuclear cells on the mouse calvarial model. *Chin Med J (Engl)* **109**, 711, 1996.
  213. Develioglul, H., Unver Saraydin, S., and Kartal, U. The bone healing effect of a xenograft in a rat calvarial defect model. *Dent Mater J* **28**, 396, 2009.
  214. Itagaki, T., Honma, T., Takahashi, I., Echigo, S., and Sasa no, Y. Quantitative analysis and localization of mRNA transcripts of type I collagen, osteocalcin, MMP 2, MMP 8, and MMP 13 during bone healing in a rat calvarial exper imental defect model. *Anat Rec (Hoboken)* **291**, 1038, 2008.
  215. Yoon, E., Dhar, S., Chun, D.E., Gharibjanian, N.A., and Evans, G.R. *In vivo* osteogenic potential of human adipose derived stem cells/poly lactide co glycolic acid constructs for bone regeneration in a rat critical sized calvarial defect model. *Tissue Eng* **13**, 619, 2007.
  216. Hirano, N., Tanabe, M., Watanabe, T., Horie, Y., Ishii, H., and Hirabayashi, S. Novel approach to calvarial bone transport using a rabbit model. *Neurol Med Chir (Tokyo)* **46**, 69, 2006.
  217. Lin, L., Shen, Q., Wei, X., Hou, Y., Xue, T., Fu, X., Duan, X., and Yu, C. Comparison of osteogenic potentials of BMP4 transduced stem cells from autologous bone marrow and fat tissue in a rabbit model of calvarial defects. *Calcif Tissue Int* **85**, 55, 2009.
  218. Takigami, H., Kumagai, K., Latson, L., Togawa, D., Bauer, T., Powell, K., Butler, R.S., and Muschler, G.F. Bone for mation following OP 1 implantation is improved by addi tion of autogenous bone marrow cells in a canine femur defect model. *J Orthop Res* **25**, 1333, 2007.
  219. Damron, T.A. Use of 3D beta tricalcium phosphate (Vitoss) scaffolds in repairing bone defects. *Nanomedicine* **2**, 763, 2007.
  220. Kold, S., Rahbek, O., Toft, M., Ding, M., Overgaard, S., and Soballe, K. Bone compaction enhances implant fixation in a canine gap model. *J Orthop Res* **23**, 824, 2005.
  221. Kold, S., Rahbek, O., Zippor, B., Bechtold, J.E., and Soballe, K. Bone compaction enhances fixation of hydroxyapatite coated implants in a canine gap model. *J Biomed Mater Res B Appl Biomater* **75**, 49, 2005.
  222. Markel, M.D., and Sielman, E. Radiographic study of homo typic variation of long bones in dogs. *Am J Vet Res* **54**, 2000, 1993.
  223. Sumner, D.R., Turner, T.M., Urban, R.M., Turek, T., See herman, H., and Wozney, J.M. Locally delivered rhBMP 2 enhances bone ingrowth and gap healing in a canine model. *J Orthop Res* **22**, 58, 2004.
  224. Sumner, D.R., Turner, T.M., Urban, R.M., Viridi, A.S., and Inoue, N. Additive enhancement of implant fixation follow ing combined treatment with rhTGF beta2 and rhBMP 2 in a canine model. *J Bone Joint Surg Am* **88**, 806, 2006.
  225. Turner, T.M., Urban, R.M., Hall, D.J., Cheema, N., and Lim, T.H. Restoration of large bone defects using a hard setting, injectable putty containing demineralized bone particles compared to cancellous autograft bone. *Orthopedics* **26**, s561, 2003.
  226. Beniker, D., McQuillan, D., Livesey, S., Urban, R.M., Turner, T.M., Blum, B., Hughes, K., and Haggard, W.O. The use of acellular dermal matrix as a scaffold for peri osteum replacement. *Orthopedics* **26**, s591, 2003.
  227. Gitelis, S., Piasecki, P., Turner, T., Haggard, W., Charters, J., and Urban, R. Use of a calcium sulfate based bone graft substitute for benign bone lesions. *Orthopedics* **24**, 162, 2001.
  228. Turner, T.M., Urban, R.M., Gitelis, S., Haggard, W.O., and Richelsoph, K. Resorption evaluation of a large bolus of calcium sulfate in a canine medullary defect. *Orthopedics* **26**, s577, 2003.
  229. Turner, T.M., Urban, R.M., Hall, D.J., Infanger, S., Gitelis, S., Petersen, D.W., and Haggard, W.O. Osseous healing using injectable calcium sulfate based putty for the delivery of demineralized bone matrix and cancellous bone chips. *Orthopedics* **26**, s571, 2003.

230. Biological Evaluation of Medical Devices, Tests for Local Effects After Implantation. International Standard Organization 10993-6, 1, 2007.
231. Kadiyala, S., Kraus, K.H., Attawia, M., and Bruder, S.P. Rapid bone regeneration in femoral defects by an autologous osteoprogenitor cell concentrate prepared using an intraoperative selective cell retention technique. Transactions of the 49th Annual Meeting of the Orthopaedic Research Society. New Orleans, LA, 2003, p. 317.
232. Kadiyala, S., Kraus, K.H., Attawia, M., Pedrozo, H., and Bruder, S.P. Use of intra operative selective cell retention technique to regenerate canine femoral segmental defects. Presented at the 5th International Meeting of the Tissue Engineering Society, Kobe, Japan, 2002.
233. Brodke, D., Pedrozo, H.A., Kapur, T.A., Attawia, M., Kraus, K.H., Holy, C.E., Kadiyala, S., and Bruder, S.P. Bone grafts prepared with selective cell retention technology heal canine segmental defects as effectively as autograft. J Orthop Res **24**, 857, 2006.
234. Kadiyala, S., Young, R.G., Thiede, M.A., and Bruder, S.P. Culture expanded canine mesenchymal stem cells possess osteochondrogenic potential *in vivo* and *in vitro*. Cell Transplant **6**, 125, 1997.
235. Burkus, J.K., Heim, S.E., Gornet, M.F., and Zdeblick, T.A. Is INFUSE bone graft superior to autograft bone? An integrated analysis of clinical trials using the LT CAGE lumbar tapered fusion device. J Spinal Disord Tech **16**, 113, 2003.
236. Medtronic. INFUSE Bone Graft/LT CAGE Lumbar Tapered Fusion Device. 2002. [www.medtronic.com/your health/lumbar degenerative disc disease/surgery/our spinal fusion product/infuse/index.htm](http://www.medtronic.com/your health/lumbar degenerative disc disease/surgery/our spinal fusion product/infuse/index.htm)
237. Wong, D.A., Kumar, A., Jatana, S., Ghiselli, G., and Wong, K. Neurologic impairment from ectopic bone in the lumbar canal: a potential complication of off label PLIF/TLIF use of bone morphogenetic protein 2 (BMP 2). Spine J **8**, 1011, 2008.
238. De Long, W.G., Jr., Einhorn, T.A., Koval, K., McKee, M., Smith, W., Sanders, R., and Watson, T. Bone grafts and bone graft substitutes in orthopaedic trauma surgery. A critical analysis. J Bone Joint Surg Am **89**, 649, 2007.
239. Friedlaender, G.E., Perry, C.R., Cole, J.D., Cook, S.D., Cierny, G., Muschler, G.F., Zych, G.A., Calhoun, J.H., La Forte, A.J., and Yin, S. Osteogenic protein 1 (bone morphogenetic protein 7) in the treatment of tibial nonunions: a prospective, randomized clinical trial comparing rhOP 1 with fresh bone autograft. J Bone Joint Surg Am **83**, S151, 2001.
240. Muschler, G.F., Nitto, H., Matsukura, Y., Boehm, C., Valdevit, A., Kambic, H., Davros, W., Powell, K., and Easley, K. Spine fusion using cell matrix composites enriched in bone marrow derived cells. Clin Orthop Relat Res **407**, 102, 2003.
241. Brockenbrough, G. Proposed legislation calls for a national hip and knee registry. <http://www.orthosupersite.com/view.asp?rID=40878>

Address correspondence to:

George F. Muschler, M.D.  
 Department of Biomedical Engineering  
 Lerner Research Institute  
 The Cleveland Clinic Foundation  
 9500 Euclid Ave. (ND20)  
 Cleveland, OH 44195

E-mail: [muschlg@ccf.org](mailto:muschlg@ccf.org)

Received: October 1, 2009

Accepted: November 5, 2009

Online Publication Date: January 7, 2010



**This article has been cited by:**

1. A. Roshan-Ghias, A. Terrier, B.M. Jolles, D.P. Pioletti. 2014. Translation of biomechanical concepts in bone tissue engineering: from animal study to revision knee arthroplasty. *Computer Methods in Biomechanics and Biomedical Engineering* **17**:8, 845-852. [[CrossRef](#)]
2. Christopher M. Heylman, Sharon Santoso, Melissa D. Krebs, Gerald M. Saidel, Eben Alsberg, George F. Muschler. 2014. Modeling and experimental methods to predict oxygen distribution in bone defects following cell transplantation. *Medical & Biological Engineering & Computing* **52**:4, 321-330. [[CrossRef](#)]
3. Gardel Leandro S., Serra Luis A., Reis Rui L., Gomes Manuela E.. 2014. Use of Perfusion Bioreactors and Large Animal Models for Long Bone Tissue Engineering. *Tissue Engineering Part B: Reviews* **20**:2, 126-146. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
4. Friis Thor Einar, Stephenson Sally, Xiao Yin, Whitehead Jon, Hutmacher Dietmar W.. A Polymerase Chain Reaction-Based Method for Isolating Clones from a Complimentary DNA Library in Sheep. *Tissue Engineering Part C: Methods*, ahead of print. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)] [[Supplemental Material](#)]
5. Dr. Thor Einar Friis, Dr. Sally Anne Stephenson, Prof. Yin Xiao, Dr. Jonathon Paul Whitehead, Dr. Dietmar Werner Hutmacher. A PCR-based method for isolating clones from a cDNA library in sheep. *Tissue Engineering Part C: Methods* **0**:ja. . [[Abstract](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
6. Livia Poser, Romano Matthys, Peter Schawalter, Simon Pearce, Mauro Alini, Stephan Zeiter. 2014. A Standardized Critical Size Defect Model in Normal and Osteoporotic Rats to Evaluate Bone Tissue Engineered Constructs. *BioMed Research International* **2014**, 1-5. [[CrossRef](#)]
7. Joong-Hyun Kim, Hae-Won Kim. 2013. Rat defect models for bone grafts and tissue engineered bone constructs. *Tissue Engineering and Regenerative Medicine* **10**:6, 310-316. [[CrossRef](#)]
8. Hamdan S. Alghamdi, Jeroen J.J.P. van den Beucken, John A. Jansen. Osteoporotic Rat Models for Evaluation of Osseointegration of Bone Implants. *Tissue Engineering Part C: Methods*, ahead of print. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
9. Max M. Villa, Liping Wang, Jianping Huang, David W. Rowe, Mei Wei. 2013. Visualizing Osteogenesis In Vivo Within a Cell-Scaffold Construct for Bone Tissue Engineering Using Two-Photon Microscopy. *Tissue Engineering Part C: Methods* **19**:11, 839-849. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)] [[Supplemental Material](#)]
10. Christopher H. Evans. 2013. Advances in Regenerative Orthopedics. *Mayo Clinic Proceedings* **88**:11, 1323-1339. [[CrossRef](#)]
11. Vitor E. Santo, Manuela E. Gomes, João F. Mano, Rui L. Reis. 2013. Controlled Release Strategies for Bone, Cartilage, and Osteochondral Engineering—Part I: Recapitulation of Native Tissue Healing and Variables for the Design of Delivery Systems. *Tissue Engineering Part B: Reviews* **19**:4, 308-326. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
12. Kai Liu, Dianqi Li, Xiangyu Huang, Kun Lv, David Ongodia, Lingling Zhu, Langming Zhou, Zubing Li. 2013. A murine femoral segmental defect model for bone tissue engineering using a novel rigid internal fixation system. *Journal of Surgical Research* **183**:2, 493-502. [[CrossRef](#)]
13. Eun Jung Kim, Aaron J. Fleischman, George F. Muschler, Shuvo Roy. 2013. Response of bone marrow derived connective tissue progenitor cell morphology and proliferation on geometrically modulated microtextured substrates. *Biomedical Microdevices* **15**:3, 385-396. [[CrossRef](#)]
14. Na Yu, Adelina Plachokova, Fang Yang, X. Frank Walboomers, John A. Jansen. Engineering of Dental Tissues: Scaffolds and Preclinical Models 409-429. [[CrossRef](#)]
15. Viviane Luangphakdy, Esteban Walker, Kentaro Shinohara, Hui Pan, Theresa Hefferan, Thomas W. Bauer, Linda Stockdale, Sunil Saini, Mahrokh Dadsetan, M. Brett Runge, Amit Vasanji, Linda Griffith, Michael Yaszemski, George F. Muschler. 2013. Evaluation of Osteoconductive Scaffolds in the Canine Femoral Multi-Defect Model. *Tissue Engineering Part A* **19**:5-6, 634-648. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)] [[Supplemental Material](#)]
16. Elena Arrigoni, Laura de Girolamo, Alessia Di Giancamillo, Deborah Stanco, Claudia Dellavia, Davide Carnelli, Marino Campagnol, Cinzia Domeneghini, Anna T. Brini. 2013. Adipose-derived stem cells and rabbit bone regeneration: histomorphometric, immunohistochemical and mechanical characterization. *Journal of Orthopaedic Science* . [[CrossRef](#)]
17. Tonya Caralla, Powrnima Joshi, Sean Fleury, Viviane Luangphakdy, Kentaro Shinohara, Hui Pan, Cynthia Boehm, Amit Vasanji, Theresa E. Hefferan, Esteban Walker, Michael Yaszemski, Vincent Hascall, Maciej Zborowski, George F. Muschler. 2013. In Vivo Transplantation of Autogenous Marrow-Derived Cells Following Rapid Intraoperative Magnetic Separation Based on Hyaluronan to Augment Bone Regeneration. *Tissue Engineering Part A* **19**:1-2, 125-134. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)] [[Supplemental Material](#)]

18. Lixin Kan Animal Models of Bone Diseases-A 353-390. [[CrossRef](#)]
19. Samit K. Nandi, Subhasish Biswas In Vivo Characterization of Biomaterials 255-297. [[CrossRef](#)]
20. A. Atala, F. K. Kasper, A. G. Mikos. 2012. Engineering Complex Tissues. *Science Translational Medicine* 4:160, 160rv12-160rv12. [[CrossRef](#)]
21. Yuchun Liu, Jerry K Y Chan, Swee-Hin Teoh. 2012. Review of vascularised bone tissue-engineering strategies with a focus on co-culture systems. *Journal of Tissue Engineering and Regenerative Medicine* n/a-n/a. [[CrossRef](#)]
22. Patrick P Spicer, James D Kretlow, Simon Young, John A Jansen, F Kurtis Kasper, Antonios G Mikos. 2012. Evaluation of bone regeneration using the rat critical size calvarial defect. *Nature Protocols* 7:10, 1918-1929. [[CrossRef](#)]
23. Wei Ji, Huanan Wang, Jeroen J.J.P. van den Beucken, Fang Yang, X. Frank Walboomers, Sander Leeuwenburgh, John A. Jansen. 2012. Local delivery of small and large biomolecules in craniomaxillofacial bone. *Advanced Drug Delivery Reviews* 64:12, 1152-1164. [[CrossRef](#)]
24. J. C. Reichert, A. Cipitria, D. R. Epari, S. Saifzadeh, P. Krishnakanth, A. Berner, M. A. Woodruff, H. Schell, M. Mehta, M. A. Schuetz, G. N. Duda, D. W. Hutmacher. 2012. A Tissue Engineering Solution for Segmental Defect Regeneration in Load-Bearing Long Bones. *Science Translational Medicine* 4:141, 141ra93-141ra93. [[CrossRef](#)]
25. O. Chan, M.J. Coathup, A. Nesbitt, C.-Y. Ho, K.A. Hing, T. Buckland, C. Champion, G.W. Blunn. 2012. The effects of microporosity on osteoinduction of calcium phosphate bone graft substitute biomaterials. *Acta Biomaterialia* 8:7, 2788-2794. [[CrossRef](#)]
26. Barbe Rentsch, Ricardo Bernhardt, Dieter Scharnweber, Wolfgang Schneiders, Stefan Rammelt, Claudia Rentsch. 2012. Embroidered and surface coated polycaprolactone-co-lactide scaffolds: A potential graft for bone tissue engineering. *Biomatter* 2:3, 158-165. [[CrossRef](#)]
27. Vitor E Santo, Manuela E Gomes, João F Mano, Rui L Reis. 2012. From nano- to macro-scale: nanotechnology approaches for spatially controlled delivery of bioactive factors for bone and cartilage engineering. *Nanomedicine* 7:7, 1045-1066. [[CrossRef](#)]
28. Roger Brooks Clinical Aspects of the Use of Stem Cells and Biomaterials for Bone Repair and Regeneration 493-520. [[CrossRef](#)]
29. Jinku Kim, Maria Hanshella R. Magno, Heather Waters, Bruce A. Doll, Sean McBride, Pedro Alvarez, Aniq Darr, Amit Vasanji, Joachim Kohn, Jeffrey O. Hollinger. 2012. Bone Regeneration in a Rabbit Critical-Sized Calvarial Model Using Tyrosine-Derived Polycarbonate Scaffolds. *Tissue Engineering Part A* 18:11-12, 1132-1139. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
30. Jinku Kim, Sean McBride, Brandi Tellis, Pedro Alvarez-Urena, Young-Hye Song, David D Dean, Victor L Sylvia, Hoda Elgendy, Joo Ong, Jeffrey O Hollinger. 2012. Rapid-prototyped PLGA/ $\beta$ -TCP/hydroxyapatite nanocomposite scaffolds in a rabbit femoral defect model. *Biofabrication* 4:2, 025003. [[CrossRef](#)]
31. Melanie J. Coathup, Karin A. Hing, Sorousheh Samizadeh, Oliver Chan, Yvette S. Fang, Charlie Champion, Thomas Buckland, Gordon W. Blunn. 2012. Effect of increased strut porosity of calcium phosphate bone graft substitute biomaterials on osteoinduction. *Journal of Biomedical Materials Research Part A* n/a-n/a. [[CrossRef](#)]
32. J.-P. Boutrand Methods and interpretation of performance studies for bone implants 271-312e. [[CrossRef](#)]
33. Fa-Ming Chen, Yi-Min Zhao, Yan Jin, Songtao Shi. 2011. Prospects for translational regenerative medicine. *Biotechnology Advances* . [[CrossRef](#)]
34. M. M. Martino, F. Tortelli, M. Mochizuki, S. Traub, D. Ben-David, G. A. Kuhn, R. Muller, E. Livne, S. A. Eming, J. A. Hubbell. 2011. Engineering the Growth Factor Microenvironment with Fibronectin Domains to Promote Wound and Bone Tissue Healing. *Science Translational Medicine* 3:100, 100ra89-100ra89. [[CrossRef](#)]
35. Kaige Lü, Deliang Zeng, Yilin Zhang, Lunguo Xia, Ling Xu, David L. Kaplan, Xinquan Jiang, Fuqiang Zhang. 2011. BMP-2 Gene Modified Canine bMSCs Promote Ectopic Bone Formation Mediated by a Nonviral PEI Derivative. *Annals of Biomedical Engineering* 39:6, 1829-1839. [[CrossRef](#)]
36. Bing Xia, Jie Wang, Lida Guo, Zujun Jiang. 2011. Effect of bone sialoprotein on proliferation and osteodifferentiation of human bone marrow-derived mesenchymal stem cells in vitro. *Biologicals* . [[CrossRef](#)]
37. Eloa R. Luvizuto, Stefan Tangl, Gerald Zanoni, Tetuo Okamoto, Celso K. Sonoda, Reinhard Gruber, Roberta Okamoto. 2011. The effect of BMP-2 on the osteoconductive properties of  $\beta$ -tricalcium phosphate in rat calvaria defects. *Biomaterials* 32:15, 3855-3861. [[CrossRef](#)]
38. Fa-Ming Chen, Li-An Wu, Min Zhang, Rong Zhang, Hai-Hua Sun. 2011. Homing of endogenous stem/progenitor cells for in situ tissue regeneration: Promises, strategies, and translational perspectives. *Biomaterials* 32:12, 3189-3209. [[CrossRef](#)]

39. O. Bruyère, R. Rizzoli, V. Coxam, B. Avouac, T. Chevalier, V. Fabien-Soulé, J. A. Kanis, J.-M. Kaufman, Y. Tsouderos, J.-Y. Reginster. 2011. Assessment of health claims in the field of bone: a view of the Group for the Respect of Ethics and Excellence in Science (GREES). *Osteoporosis International* . [[CrossRef](#)]
40. Ericka M. Bueno, Julie Glowacki. 2011. Biologic Foundations for Skeletal Tissue Engineering. *Synthesis Lectures on Tissue Engineering* 3:1, 1-220. [[CrossRef](#)]
41. Jeremy J. Reid, Jared S. Johnson, Jeffrey C. Wang. 2011. Challenges to bone formation in spinal fusion. *Journal of Biomechanics* 44:2, 213-220. [[CrossRef](#)]
42. B.D. Boyan, M.I. Baker, C.S.D. Lee, A.L. Raines, A.S. Greenwald, R. Olivares-Navarrete, Z. Schwartz Bone Tissue Grafting and Tissue Engineering Concepts 237-255. [[CrossRef](#)]
43. Ludmila Luca, Anne-Laure Rougemont, Beat H. Walpoth, Ludovic Boure, Andrea Tami, James M. Anderson, Olivier Jordan, Robert Gurny. 2011. Injectable rhBMP-2-loaded chitosan hydrogel composite: Osteoinduction at ectopic site and in segmental long bone defect. *Journal of Biomedical Materials Research Part A* 96A:1, 66-74. [[CrossRef](#)]
44. Lauren Martz. 2010. Cell-free joint regeneration. *Science-Business eXchange* 3:32. . [[CrossRef](#)]
45. Fa-Ming Chen, Min Zhang, Zhi-Fen Wu. 2010. Toward delivery of multiple growth factors in tissue engineering. *Biomaterials* 31:24, 6279-6308. [[CrossRef](#)]
46. Chang H Lee, James L Cook, Avital Mendelson, Eduardo K Moiola, Hai Yao, Jeremy J Mao. 2010. Regeneration of the articular surface of the rabbit synovial joint by cell homing: a proof of concept study. *The Lancet* 376:9739, 440-448. [[CrossRef](#)]